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Growth factor receptors define the linkage point between extracellular events and the 
intracellular responses, activating a plethora of signalling pathways. Transmembrane 
receptors proteins play critical roles in either development and maintenance of the cellular 
biology and are strongly correlated with the occurrence of disease (Shor NF, 2005). More 
than other, the brain tissue is the most sensitive to the presence of growth factors and, the 
differential expression of their specific receptors, amplify the complexity of the system. 
Neurotrophin are the specific growth factors in the nervous system. They were first 
identified as survival factors for sympathetic and sensory neurons but it is appreciated that 
they regulate many aspects of neuronal development and function, including synapse 
formation and synaptic plasticity (Lewin & Barde 1996; Bibel & Barde 2000; Kaplan & 
Miller 2000; Huang et al. 2001; Poo 2001; Shooter 2001; Sofroniew et al. 2001; Dechant & 
Barde 2002; Chao 2003; Huang & Reichardt 2003; Lu et al. 2005). The first Neurotrophin 
identified was the Nerve Growth Factor (NGF), searching for survival factors that could 
explain the deleterious effects of deletion of target tissues on the subsequent survival of 
motor and sensory neurons (Levi-Montalcini 1987; Shooter 2001). The second neurotrophin 
to be characterized was the Brain-Derived Neurotrophic Factor (BDNF) purified from pig 
brain as a survival factor for several neuronal populations not responsive to NGF (Barde et 
al. 1982). Given the conserved features of the sequences, it has been easier to clone the 
other members of the family. Together with the NGF (Nerve Growth Factor) and BDNF 
(Brain Derived Neurotrophin Factor) other two factors are reported so far in mammals, the 
NT-3 and the NT-4 (Neurotrophin-3 and 4). It is known that neurothrophins have an 
important role in the development and function of neurons either in the central and in the 
peripheral nervous systems, including precursor proliferation and commitment, cell 
survival, axon and dendrite growth, membrane trafficking, synapse formation and function, 
as well as glial differentiation and interactions with neurons. Biological effects of each of 
the four mammalian neurotrophins are mediated through activation of one or more of the 
three members of the tropomyosin-related kinase (Trk) family of receptor tyrosine kinases 
(TrkA, TrkB and TrkC). In addition, all neurotrophins activate the p75 neurotrophin 
receptor p75NTR, a member of the tumour necrosis factor receptor superfamily. 
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NGF is the best characterised member of the family and is known to signal for opposite 
effects through interaction with two distinct families of receptors: activation of cell survival 
by TrkA and induction of cell death by binding to p75NTR. Engagement of Trk receptors 
leads to activation of well characterized pathway like Ras, phosphatidylinositol 3-kinase, 
phospholipase C-gamma1 and the mitogen-activated protein kinases. On the other side, the 
molecular mechanisms mediated by p75NTR still remain to define even though the JNK, 
NF-κB and ceramide have been implicated (Huang and Reichardt, 2003). Preclinical studies 
point to the therapeutic potential of neurotrophic factors in preventing or slowing the 
progression of neurodegenerative conditions. Given the difficulties inherent with a protein 
therapeutic approach to treating central nervous system disorders, increasing attention has 
turned to the development of alternative strategies related to the signalling pathways 














1.0 Neurotrophins and Neurotrophin Receptors 
 
The neurotrophins and their genes share homologies in sequence and structure and the  
organization of the genomic segments adjacent to these genes also resulted to be similar. 
Together, these observations provide evidence that the neurotrophin genes have arisen 
through successive duplications of a portion of the genome derived from an ancestral 
chordate (Hallbook 1999). Their genes share many similarities, including the existence of 
multiple promoters. The protein product of each gene includes a signal sequence and a 
prodomain, followed by the mature Neurotrophin sequence (Hempstead B. L. 2006). Thus, 
each gene product must be processed by proteolysis to form a mature protein. A recent work 
has demonstrated that regulation of their maturation is an important post-transcriptional 
control point that limits and adds specificity to their actions (Lee et al. 2001). The mature 
neurotrophin proteins are non-covalently associated homodimers. Although some 
neurotrophin monomers are able to form heterodimers with other neurotrophin monomers in 
vitro, there is no evidence that these heterodimers exist at significant concentrations in vivo. 
Each of these four proteins shares a highly homologous structure with features tertiary fold 
and cysteine knot that are present in several other growth factors, including transforming 
growth factor-β (TGF-β) and platelet derived growth factor (PDGF). Additional 
neurotrophins have been isolated from fish, where NT-6 and NT-7 have been characterized 
but they do not have orthologues in mammals or birds. The biological effect of the 
neurotrophins is mediated by interaction with two distinct classes of receptors: 
 
• Trk receptors  (tropomyosin- related kinase) 





Fig. 1. Neurotrophin and Neurotrophin receptors. This illustrates the major interactions of each of the four 
mammalian neurotrophins. Each proneurotrophin binds p75NTR, but not the Trk receptors. Following maturation 
through proteolysis of the proneurotrophins, each mature Neurotrophin is able to bind and activate p75NTR, but 
exhibits more specific interactions with the three Trk receptors. NGF binds specifically TrkA; BDNF and NT4 
recognize TrkB; NT3 activates TrkC. In some cellular contexts, NT3 is also able to activate TrkA and TrkB with less 
efficiency. Differential splicing generates isoforms of TrkB and TrkC that have truncated cytoplasmic domains lacking 
a tyrosine kinase motif. Splicing also generates an isoform of TrkC with a small insert in the kinase domain that affects 
substrate specificity. Splicing of exons that generate the extracellular domain of each Trk receptor results in the 
expression of receptors with small peptide inserts between the second immunoglobin and transmembrane domains that 














1.1 The Trk receptors 
 
TrkA was originally characterized as a transforming oncogene in which tropomyosin was 
fused to an unknown tyrosine kinase (Martin-Zanca et al., 1989). The corresponding proto-
oncogene was shown to be a member of a highly related family of transmembrane tyrosine 
kinases which were expressed in discrete neuronal populations and which bound and were 
activated by specific neurotrophins, with TrkA preferentially binding NGF, TrkB preferring 
BDNF and NT-4/5, and TrkC interacting with NT-3 (Klein et al., 1990, 1991a,b; Cordon-
Cardo et al., 1991; Kaplan et al.,1991a,b; Lamballe et al., 1991; Soppet et al., 1991; Squinto 
et al., 1991; Ip et al., 1993b). In the absence of p75NTR, high concentrations of NT-4/5 can 
activate TrkA and likewise, NT-3 can activate TrkA and TrkB. NT-3 is therefore a non-
preferred ligand for TrkA and TrkB, and NT-4 is a non-preferred ligand for TrkA (Segal 
and Greenberg, 1996). All Trk receptors are Type I transmembrane proteins that are 
members of the receptor tyrosine kinase superfamily (Martin-Zanca et al., 1989; reviewed in 
Ip and Yancopoulos, 1994; Barbacid, 1995). The extracellular domains (ECDs) of the Trk 
receptors contain two cysteine-rich regions (domains 1 and 3) flanking a leucine-rich repeat 
(domain 2), followed by two immunoglobulin (IgG)-like domains in the juxtamembrane 
region (domains 4 and 5; Windisch et al., 1995). Binding and deletion studies on TrkA, 
TrkB and TrkC indicate that domain 5 is responsible for neurotrophin binding (Urfer et al., 
1995, 1998; Perez et al., 1995; Ultsch et al., 1999), with the second leucine-rich domain 


















1.2 The low affinity Neurotrophin receptor p75NTR 
 
The first Neurotrophin receptor discovered was p75 neurotrophin receptor (p75NTR), 
initially identified as a low-affinity receptor for NGF, subsequently has been shown to bind 
each of the neurotrophins with a similar affinity (Rodriguez-Tebar et al. 1990; Frade and 
Barde 1998; Chao and Hempstead, 1995). Based on the primary sequence and secondary 
structure, p75NTR belongs to the Fas-tumor necrosis factor (TNF) receptor superfamily 
with an extracellular domain that includes four cysteine-rich motifs, a single transmembrane 
domain and a cytoplasmic domain that includes a juxtamembrane domain and a ‘death’ 






Fig. 2. Schematic representation of p75NTR. Extracellular, transmembrane and intracellular domains of the receptor 
on the left. Solution structure of the death domain of rat p75ICD on the right. Ribbon representation of residues 336–
416. The positions of the N-terminal residues of the helices are labelled. (Blochl and Blochl, 2007; Liepinsh et al, 1997) 
 
Recent studies have identified new mechanisms able to process the receptor with subsequent 
generation of soluble peptides supposed to exert new cytoplasmic or nuclear functions 
(Kanning KC et al, 2003; Podlesniy et al, 2006). 
Since p75NTR does not contain a catalytic motif, the signal mediation depends on the 
interaction with cytoplasmic proteins important for regulating neuronal survival and 
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differentiation as well as synaptic plasticity. The complex signalling of p75NTR makes it 
difficult to formulate a unified functional model for this receptor. Indeed, many trophic and 
apoptotic activities are integrated with that of other receptors and mechanisms. Synergistic 
and antagonistic interactions of p75NTR and Trk receptors such as complex formation, 
mutual inhibition, or negative control of Trk effects by p75NTR have been extensively 
investigated without defining a general model (Dechant 2001; Huang and Reichardt 2003; 





Fig. 3. p75 neurotrophin receptor and interactor receptors. P75NTR has been referred to as a ‘low-affinity’ 
Neurotrophin receptor, but this definition should be avoided because proNGF binds p75NTR with an affinity similar to 
that of nerve growth factor (NGF) binding to TrkA. Although it lacks a kinase domain, p75NTR can cooperate with 
many different protein partners and form multimeric receptor complexes to produce a number of cellular responses, 
including apoptosis, neurite outgrowth and myelination111–113. So far, sortilin61, LINGO-1, Nogo-66 (NgR)114 and 
Trk receptors115 have been identified as co-receptors. In addition to extracellular interactions that yield multimeric 
receptor complexes, the intracellular domain of p75NTR can also interact with many different adaptor and signalling 
proteins. These include neurotrophin-receptor-interacting MAGE (melanoma-associated antigen) homologue 
(NRAGE)116, neurotrophin-associated cell death executor (NADE)117, TNF (tumour necrosis factor)-receptor-
associated factors 2 and 6 (TRAF2 and TRAF6)118,119, and neurotrophin-receptor-interacting factor (NRIF)120,121. 
GDI, guanine-nucleotide dissociation inhibitor; MAG, myelin-associated glycoprotein; OMGP, oligodendrocyte myelin 
glycoprotein; RhoA, small G protein. 
 
 
Beside the more characterized interaction with the Trk receptors, p75NTR can  also interact 
with other different cytoplasmic receptors. p75NTR can be influenced by co-receptors like 
NgR and Lingo1, which cooperate to prevent p75NTR activation, or sortilin, which shares 
the pro-neurotrophin ligands with p75NTR and directs p75NTR activity towards apoptosis 
(Nykjaer et al. 2004; reviews: Bronfman and Fainzilber 2004; Ceni and Barker 2005). 
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Taking together, all these studies suggest that rather than being just a co-receptor, all the 
identified interactors for p75NTR can modulate, inhibit or enhance its activities. The results 
is that the actions of the receptor may be explained by considering three different biological 
outcomes: 
 
1. positive regulation of cell survival and differentiation 
2. constitutive pro-apoptotic activation 































1.1.1 p75NTR as a positive regulator of cell survival and differentiation 
In neurotrophin-responsive neuronal populations, p75NTR and Trk receptor members are 
frequently co-expressed, particularly in the vertebrate peripheral nervous system. P75NTR 
provides a positive modulatory influence on TrkA function by increasing the number of 
high affinity binding sites (Mahadeo et al, 1994). Regulation of high-affinity site formation 
by co-expression of TrkA and p75NTR provides an explanation for how these receptors 
may cooperate to increase Neurotrophin responsiveness during development. Indeed, 
neuronal cell lines express both receptors have an enhanced autophosphorylation of TrkA, 
leading to a faster differentiative response with NGF (Verdi et al, 1994). The general feeling 
proposes that the cell survival is  enhanced by a higher ratio of p75NTR to Trk receptors. 
Indeed, considering p75NTR null mice it has been found a selective losses in sensory and 
sympathetic innervations. From neonatal p75NTR null mice, sympathetic neurons required 
higher concentrations of NGF to survive than neurons from normal mice at earlier 
developmental stages (Lee et al, 1994). To explain how p75NTR can modulate Trk 
receptors functions two models have been proposed so far. The first is a ligand passing 
mechanism, which predicts that the high-affinity state is the result of ligand presentation by 
p75NTR to the TrkA receptor (Barker and Shooter, 1994). The second model predicts that 
p75NTR and TrkA are capable of a ligand-independent association, which produces a high 
affinity binding interaction. (Chao and Hempstead, 1995). The second model would predict 
that conformational changes would occur to facilitate ligand binding. (Ross et al, 1996) All 
of these observations are consistent with the hypothesis that p75NTR can serve as a positive 







1.1.2. p75NTR as a constitutively active pro-apoptotic receptor  
In the1993 Bredesen and colleagues hypothesized that p75NTR was a death receptor. Based 
on the observation that immortalized neural cells overexpressing p75NTR display an higher 
rate of apoptosis in response to serum withdrawal, they proposed a mechanism of ligand-
indipendent death (Rabizadeh et al, 1993). According to this model, apoptosis promoted by 
p75NTR can be rescued after binding to NGF. How NGF gives a survival signal through 
binding to p75NTR has not been established. However, the correlation between high levels 
of p75NTR expression and susceptibility to apoptosis after growth factor withdrawal has 
been proved also in PC12 cells supporting this mechanism of cell death (Barrett and 
Georgiou, 1996). Furthermore, down-regulation of p75NTR expression in neonatal dorsal 
root sensory neurons, using an antisense strategy, reveals enhanced survival (Barrett and 
Bartlett, 1994). The phenotype of the p75NTR null mice supports a role in neuronal survival 
(Davies et al., 1993; Lee et al., 1994a,b) but an apoptotic function as well. Analysis of mice 
has revealed a significantly higher number of cholinergic neurons in the basal forebrain in 
p75NTR -/- mice compared to wild type controls (Van der Zee et al., 1996; Yeo et al., 
1997). These observations indicate that the absence of p75NTR resulted in enhanced 
survival, similar to the antisense effects observed in postnatal sensory neurons (Barrett and 









1.1.2. Ligand-dependent p75NTR cell death 
Several lines of evidence now firmly support that neurotrophins can actively kill cells 
through direct engagement of its p75NTR receptor. Both in vitro and in vivo evidence has 
indicated that neurotrophins and p75NTR are required for apoptosis of selective cell 
populations. In contrast to the model of NGF rescue through p75NTR, other studies 
demonstrate that cultured trigeminal neurons at embryonic age E10 are killed by NGF 
through binding to p75NTR (Davey and Davies, 1998). The cell death role of p75NTR is 
elicited upon injury or traumatic conditions. Similarly, cultured glial cells, such as fully 
differentiated oligodendrocytes, express elevated levels of p75NTR are effectively killed by 
NGF (Casaccia-Bonnefil et al., 1996). The apoptotic effects of p75NTR are not only 
enhanced by NGF binding but, in certain conditions, also by high concentrations of BDNF 
and other neurotrophins. Postnatal sympathetic neurons express p75NTR and TrkA, but are 
killed by BDNF-mediated activation of p75 (Bamji et al., 1998). BDNF for survival are 
killed by NT-4 through binding to p75NTR (Agerman et al., 1999). Primary cell culture 
experiments demonstrated that p75NTR was necessary for neuronal cell survival promoted 
by BDNF, but NT-4 binding to p75 induced cell death. This remarkable set of observations 
indicates that p75NTR and Trk receptor can simultaneously influence life-and-death 
decisions in neurons depending upon which ligands are available. An issue raised by these 
experiments is that although all neurotrophins (NGF, BDNF, NT-3, and NT-4) bind to 
p75NTR with similar affinity, each neurotrophin may exert different effects on cell function 
and viability through p75NTR. For example, the effect of NGF on oligodendrocyte cultures 
could not be reproduced by similar concentrations of BDNF or NT-3. Furthermore, in PC12 
cells treated with antisense oligonucleotides to downregulate TrkA expression, BDNF but 
not NGF can rescue cells from serum-withdrawal (Taglialatela et al., 1996). A very likely 
explanation for the effect of distinct neurotrophins in the oligodendrocyte system is the 
presence of TrkB and TrkC receptors in these cells (Cohen et al., 1996).An alternative 
explanation for cells not expressing other Trk receptors is the differential ability of 
neurotrophins to activate distinct signal transduction pathways (Carter et al., 1996; Carter 
and Lewin, 1997). This hypothesis is also supported by striking differences in the kinetics of 
binding and the degree of positive cooperativity of each neurotrophin to p75NTR 
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(Rodriguez-Tebar et al., 1990, 1992). A related explanation may involve different adaptor 






















2. Downstream cell death signalling of p75NTR 
Since the many effects modulated by p75NTR, it is reasonable the identification of  as such  
high number of interactors that bind the intracellular domain of the receptor.  Several 
different p75NTR interacting molecules, with and without catalytic activity, have been 
identified to date (Gentry et al, 2004). Non-catalytic interactors include a series of 
scaffolding and adaptor-like molecules, such as caveolin-1 (Bilderback et al, 1997), 
Bex3/NADE (Mukai et al, 2000) and TRAF6 (Khursigara et al, 1999; Ye et al, 1999); larger 
proteins containing zinc-finger domains with some degree of nuclear localization, such as 
NRIF1/2 (Casademunt et al, 1999) and SC-1 (Chittka and Chao, 1999); and members of the 
MAGE homology domain family, such as NRAGE (Salehi et al, 2000) and necdin 
(Tcherpakov et al, 2002) with proposed roles in the regulation of apoptosis. p75NTR 
interactors with catalytic activity include serine–threonine kinases involved in interleukin 
and NF-kB signaling, such as IRAK (Mamidipudi et al, 2002) and RIP2 (Khursigara et al, 
2001); a protein tyrosine phosphatase (FAP-1) (Irie et al, 1999); and the small GTPase 
RhoA (Yamashita et al, 1999). How these p75NTR-interacting proteins connect to 
downstream signaling pathways and cellular responses is still not clear. Some of the 
principal downstream events characterized in p75NTR signalling include ceramide 
production (Dobrowsky et al, 1994) and activation of the transcription factor NF-kB (Carter 
et al, 1996) and the c-Jun kinases JNK1–3 (Casaccia-Bonnefil et al, 1996; Friedman, 2000; 









3. p75NTR and the neurodegeneration 
Alzheimer’s Disease (AD) is the most common form of dementia in the elderly that affects 
more that 20 million people world wide . It is characterized by progressive memory loss and 
confusion depending on neuropathological changes that include loss of neurons, 
extracellular deposition of amyloid peptide in the neuritic plaques and intracellular 
deposition of hyperphosphorylated tau protein (‘tangles’). One pathological feature of AD is 
the senile plaque, whose major component is the amyloid β-peptide (Aβ). Accumulation of 
a 37-43 aminoacid peptide, 
amyloid peptide (Aβ), that derives 
from multiple proteolytic 
cleavage of a large 
transmembrane precursor, 
amyloid precursor protein (APP), 
by specific enzymes belonging to 
the secretase family.  
 
Fig.  4. Representation of senile plaques in 
AD brain 
  
The generation of Aβ peptide is a physiological peptide derives from an amyloid precursor 
protein that can be processed in different ways by different sets of enzymes. One pathway 
leads to amyloid plaque formation (amyloidogenic), while another does not (non-
amyloidogenic).  Usually about 90% of APP enters the non-amyloidogenic pathway, and  
10% the amyloidogenic one, but these ratios can change due to mutations, environmental 
factors, as well as the age of the individual. Cleavage products from both these pathways 
may play important roles in neural development and function.  
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 Fig. 5. APP Processing α-secretase and γ-secretase produce non-plaque forming p3, while β-secretase and γ-secretase 
produce amyloid plaque-forming Aβ.  The different regions of the APP protein are indicated. 
 
In the non-plaque-forming pathway, APP is cleaved first by α-secretase to yield a soluble 
N-terminal fragment (sAPPα) and a C-terminal fragment (CTFa).  sAPPα may be involved 
in the enhancement of synaptogenesis, neurite outgrowth and neuronal survival, and are 
considered to be neuroprotective.  CTFα is retained in the membrane, where it is acted upon 
by presenilin-containing γ-secretase to yield a soluble N-terminal fragment (p3) and a 
membrane-bound C-terminal fragment (AICD, or APP intracellular domain).  AICD may be 
involved in nuclear signalling via transcriptional regulation as well as axonal transport 
through its ability to associate with a host of different proteins. 
In the plaque-forming pathway, APP is cleaved first by a different enzyme, β-secretase (a 
transmembrane aspartic protease), yielding a soluble N-terminal fragment (sAPPβ) and a 
membrane-bound C-terminal fragment (CTFβ).  This cut is made closer to the N-terminal 
end of APP than the cut with α-secretase, making CTFβ longer than CTFα.  CTFβ is then 
acted upon by γ-secretase (as occurred in the previous pathway), yielding a membrane-
bound C-terminal fragment (AICD) the same as before, and a soluble N-terminal fragment 
(amyloid-β, or Aβ) that is longer than p3.  
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Aβ can be accumulated in the extracellular cortex neurons and basal forebrain nuclei where 
it can aggregate to form amyloid plaques exerting deleterious effects on neuronal and 
synaptic function, ultimately causing neuronal cell death. Major part of AD cases are 
sporadic without a known aetiology 
connection. However, some cases are 
associated with mutations of genes that 
are involved in the APP expression, 
proteolytic processing, or in the 
changes in Aβ stability or aggregation. 
These in turn result in a chronic 
imbalance between Ab production and 
clearance. The gradual accumulation of 
aggregated Aβ may initiate a complex, 
multistep cascade that includes gliosis, 
Fig. 6. Progression of neurodegeneration in brain in AD        inflammatory changes and formation of 
neurofibrillary tangles.  
In this scenario, an hypothesis that has been put forward to explain the aetiology of AD 
arises the connection between the occurance of the pathology with the Neurotrophic factors, 
suggesting a causal link (Rabizadeh et al, 1994).  
An early indicator of Alzheimer’s disease is the degeneration of the cholinergic basal 
forebrain neurons, which express the highest levels of the pan neurotrophin receptor 
(p75NTR) in the adult brain (Gibbs et al. 1989). These neurons are dependent on NGF-
mediated survival signalling through TrkA which, unlike p75NTR, is reduced in 
Alzheimer’s disease patients. In addition, p75NTR is also expressed in the Trk-negative, 
degenerating cortical neurons of Alzheimer’s disease sufferers, a situation which is not 
reflected in healthy elderly subjects (Mufson et al. 1992). Furthermore, the neurotrophins, 
acting differentially through Trk receptors and p75NTR, appear to regulate the expression 
and cleavage of the amyloid protein precursor (APP; Costantini et al. 2005a), potentially 
regulating the generation of Aβ with ageing. Given that up-regulation and ligand activation 
of p75NTR have been widely shown to mediate neural cell death in animal models of 
neurodegenerative disease (Coulson et al. 2000a; Dechant and Barde 2002; Roux and 
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Barker 2002) and that the pro-form of NGF, which selectively binds to p75NTR to promote 
neuronal death (Lee et al. 2001), is increased in Alzheimer’s disease (Fahnestock et al. 
2001; Peng et al. 2004), the receptor is a strong candidate for independently mediating the 
degeneration occurring in Alzheimer’s disease.  
 
3.1 Aβ binds to p75NTR  
Further support to the hypothesis that p75NTR could be a mediator of the cytotoxic effect 
induced by deposition of Aβ derives from the study of Mina Yaar in which they proved the 
direct binding. In 1997 Yaar et al. reported that Aβ 1–40 binds to and immunoprecipitates 
with p75NTR (Yaar et al. 1997). In the brain, this protein is expressed at the highest level 
by the cholinergic neurons of the basal nuclear complex, which are sensitive to Aβ 
neurotoxicity, and undergo degeneration in AD. In contrast, the neurons of other cholinergic 
complexes in the brain (pedunculoponine and lateral tegmental nuclei) neither express 
p75NTR nor undergo degeneration in AD, suggesting that the vulnerability of basal nuclear 
neurons and their projections may be related to their high-level expression of p75NTR 
(Rabizadeh et al,1994). The use of rat cortical neurons and a cell line engineered to express 
p75NTR has demonstrated that P75NTR binds specifically fAβ, and that this binding is 
followed by apoptosis (Yaar et al, 1997; 2002). The binding of Aβ to P75NTR activates 
NF-kB in a time- and dose-dependent manner. Blockade of the interaction between Aβ and 
p75NTR with nerve growth factor or inhibition of NFKB activation by curcumin or NF-κB 
SN50 attenuated or abolished Aβ-induced apoptotic cell death (Kuner et al, 1998). Other 
studies have shown that P75NTR may be present in a trimer form that binds Aβ to induce 
receptor activation, and that Aβ binds to both the p75NTR trimer and the P75NTR 
monomers. In neuronal hybrid cells, it has been confirmed that p75NT mediates Aβ 
toxicity, and that the p75NTR-mediated Aβ neurotoxicity involves Go, c-jun kinase, 
reduced nicotinamide adenine dinucleotide oxidase and caspases 9/3 (Tsukamoto et al, 
2003). However, it has been reported that, in human primary neurons in culture, p75NTR 
protects against extracellular Aβ-mediated apoptosis. This neuroprotection might occur 
through a P13Kdependent pathway. The reason for this difference may be explained by 
differential activation of a signal transduction pathway in primary neurons versus tumour 
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cell lines, a cell-type or species-specific effect of Aβ, or a differential expression of the 
other neurotrophic receptors (Zhang et al, 2003). Along with this hypothesis, other studies 
focused their attention on the possible mechanism that can be activated after binding of Aβ 
to p75NTR. In the 2002 Perini et al identified a specific cytoplasmic domain that resulted to 
be essential for the mediation of the Aβ cell death (Perini et al, 2002).  To this purpose, Aβ 
has been tested for the neuronal toxicity on a SK-N-BE neuroblastoma cell line devoid of all 
Neurotrophin receptors, and on several SK-N-BE derived cell clones either expressing the 
full-length or truncated forms of p75NTR . It has been found that p75NTR plays a direct 
role in Aβ cell death through the signalling function of the death domain (DD). 
Furthermore, it has been showed that the cell death is caspase dependent, in particular 








































































p75NTR signals cell-death upon binding to the Aβ peptide and 
recruiting TNFR1–associated death domain (TRADD) 
 
1.1 p75NTR/TNFR1 conserved death domain aminoacidic residues are 
required to trigger Abeta peptides induced cell death 
 
In the past years it has been shown that p75NTR signals cell death upon binding to the β-
amyloid peptide (Aβ) (Yaar et al,1997; Kuner et al,1998; Costantini et al,2005). 
In a previous study published from this laboratory, it has been proposed that p75NTR 
activates apoptosis through the Death Domain (DD) that characterizes the cytoplamic 
sequence of the receptor (Perini et al,2002). In this further study, we deeper analyze the 
mechanism by which p75NTRDD signals cell death putting forward a more detailed map of 
the domain. Furthermore, we describe one of the possible initial steps of the cytotoxic 
effects induced by Aβ correlating p75NTR with the changes that occur in Alzheimer’s 
disease. 
In our studies the cell system of reference is a Neuroblastoma cell line (SK-N-BE) that does 
not express any neurotrophic receptors at detectable level and that allow us to better define 
the unique role of the p75NTR in the signal transduction induced by Aβ (Bunone et al., 
1997)  
Using derived Neuroblastoma cell pools of SK-N-BE engineered to express full-length or 
various truncated forms of p75NTR, we have already demonstrated that p75NTR is 
involved in the direct signaling of cell death Adependent through activation of 
caspases-8 and 3, inducing the production of reactive oxygen intermediates and formation 
of oxidative stress (Perini et al,2002). 
To better understand the molecular mechanism by which p75NTR mediates this cell death, 
we reasoned on the assumption that p75NTR is devoid of any intrinsic enzymatic activity so 
it should signal, across the cell membrane, through protein-protein interaction, likely 
involving aminoacidic residues placed on the surface of the intracellular p75NTR-DD. 
Starting from this observation, the first aim of our experiments was to characterize which 
residues were more responsible or more involved in the transduction of the Aβ dependent 
cell death. Previous NMR and solvent accessibility studies have analyzed the conformation 
of the p75NTR DD highlighting the amino acidic residues putatively located on the outer 
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surface. (Liepinsh et al,1997) Knowing the tridimensional structure, we decided to 
mutagenize the identified outer residue by site-specific mutagenesis through Alanine-
substitution. (Cunningham & Wells,1989). 
We targeted different residues listed as follow: 
 
• D355 (Interhelical loop I) 
• H359 and E363 (Helix II) Q367 (Interhelical loop II) 
• P368 and E369 (Helix II) A378 (Interhelical loop III) 
• D392 and S393 (Interhelical loop IV) 
• D397 (Helix V) 
• R404, R405, Q407 and R408 (Interhelical loop VI) 
• D410 and E413 (Helix VI) 
 
The specific residues are numbered following the order in the original paper (Liepinsh et 
al,1997)          
All the residues found by NMR to be located at the surface of the p75NTR DD have been 
substituted to A but the A378 substituted to D. (Residues in the helix I have been excluded 
from this analysis because they were not deleted in the p75NTR∆DD truncated mutant used 
in the previous study Perini et al,2002). For all the PCR-mediated site-specific mutagenesis 
we used the rat p75NTR cDNA cloned in the pcDNA3 expression vector (p75NTR/pcDNA). 
The mutated plasmids have been used to generate stable pools of SK-N-BE. 
Subsequentially, cells expressing wild-type or mutant p75NTR, carrying either single or 
multiple substitutions (Table 1 and Fig 1A) have been analyzed to determine if and in which 
way they could be involved in the mediation of cell death induced by Aβ. Pools of SK-N-
BE have been exposed to the aggregated Aβ(25-35) as well as to the Aβ(35-25) reverse 
peptides as negative control. The treatment has been performed for 48 hours the levels of 
cell death have been evaluated by microscopic analysis after TUNEL labeling. 
Analyzing the cell death levels after Aβ treatment, it was evident that not all the substituted 
residues were involved at the same way in mediating cytotoxicity. Expression of the 
Rp75NTR-C, Rp75NTR-E and Rp75NTR-F mutant receptors decreases the level of Aβ peptide 
induced cytotoxicity (fig 1B) whereas the Rp75NTR-A, B, D and G did not show any changes 
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in the levels of cell death. Therefore, our first conclusion was that only the most C-terminal 
half of p75NTR-DD (between interhelical region III and the helix VI) is required for the cell 




Fig. 1. Role of the p75NTR death domain outer aminoacidic residues in Aβ–induced cytotoxicity. (A) Schematic 
representation of the rat p75NTR receptor with details of the death domain. The aminoacidic residues target of the site 
directed mutagenesis in the different mutant p75NTR expression vectors (constructs A to G) are indicated (construct A: 
aa 355-359-363; construct B: aa 367-368-369; construct C: aa 378; construct D: aa 392-393; construct E: aa 397; 
construct F: aa 404-405-407-408-410-413; construct G: aa 407). The mutated amino acid are putatively located at the 
death domain surface and their position in the death domain alpha-helix (α) or interhelical loop (I) are indicated. The 
different expression vectors has been transfected in neuroblastoma SK-N-BE cells and stably transfected pools have 
been selected. (B) Aβ cytotoxicity analysis by TUNEL labelling and Ethidium Bromide nuclear counterstaining. SK-N-
BE cell pools expressing either wild type p75NTR (p75WT) or the indicated mutant p75NTR were exposed to A(25-35) 
20 M (A-Beta) or A(35-25) 20 M (control) for 48 hrs, then cell death level has been evaluated. Plotted cell death 
results are shown. SK-N-BE cells stably transfected with the empty pcDNA vector are used as negative control. Data 
are means + ES of three experiments. 
 
These first data gave us a new insights and new interests to better define the protein 
conformation of the p75NTRDD. Indeed, we considered that, since its primary sequence 
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and secondary structure, p75NTR belongs to the Superfamily of the Tumor Necrosis Factor 
Receptors, which contains also the TNFRI itself and Fas receptors. 
The similarity of the structures and the homology of the sequences between the death 
domains of p75NTR, TNFRI and Fas receptor have been previously analyzed in a paper by 
Barbara Chapman (Chapman et al, 1995). In that study the comparison of DDs sequences 
from p75NTR, TNFR1 and Fas from human, mouse and rat using a matrix procedure to detect 
low level of aminoacid identity, has let to evaluate 32,8% identity between p75NTR and 
TNFR1 and 25,4% between TNFR1 and Fas (Chapman,1995). Notably, some specific 
residues were found almost completely conserved and more importantly four of them have 
been previously demonstrated to be necessary for TNFα-induced TNFR1-mediated cell 
death (Tartaglia et al,1993). In detail, the residues E369, W378, D390, I408 are highly 
conserved between the DD of p75NTR and TNFRI and correspond to the following p75NTR 
residues: E377, W388, D397 and I411. (figure Rasmol!) 
Interestingly, our first screening revealed that mutations in conserved residues or very close 
to them (A378D, D397A, and residues substituted in the construct p75NTR-F) are sufficient 
to block almost completely the cytotoxic signal (Fig.1B). 
To extend our analysis we also mutated the E377, W388 and I411 residues into Ala (Fig. 
2A). Interestingly, as shown for D397 (Fig. 1B) also E377, W388 and I411 seem to be 
crucial for Aβ triggered cytotoxicity. 
 28 
 
Fig. 2 Role of the p75NTR/TNFR1 conserved Aminoacidic residues in Aβ–induced cytotoxicity (A) Schematic 
representation of the rat p75NTR receptor with details of the death domain. Mutant of p75NTR cDNA were generated by 
PCR introducing substitution to A of the indicated amino acid residues conserved with TNFR1 (aa E377, W388, and 
I411). The different expression vectors has been transfected in neuroblastoma SK-N-BE cells and stably transfected 
pools have been selected. (B) Aβ cytotoxicity analysis by TUNEL labelling and Ethidium Bromide nuclear 
counterstaining. SK-N-BE cell pools expressing either wild type p75NTR (p75WT) or the indicated mutants p75NTR (377, 
388, 411) were exposed to A(25-35) 20 M (A-Beta) or A(35-25) 20 M (control) for 48 hrs, then cell death 
has been evaluated. SK-N-BE cells stably transfected with the empty pcDNA vector are used as negative control. Data 
are means + ES of three experiments. 
 
We found that indeed single point mutations are enough to abate almost to the background 
level the percentage of TUNEL positive nuclei after 48 hours of Aβ exposure. 
All together these data suggest that, upon Aβ peptide activation, p75NTR can signal cell 
death through some specific areas of its DD and importantly these areas include conserved 






1.2 TRADD dominant negative is able to interfere with p75NTR-dependent 
Aβ− peptide induced cell death. 
 
The first set of experiments we performed clarified that, after exposure to the A peptide, 
p75NTR signals cell death in Neuroblastoma cell line and we identified specific Death 
Domain residues required in mediating cell death. 
The identification of the conserved residues between p75NTR and TNFR1 represented a 
moment of discussion that allow us to speculate about the possible mechanisms by which 
p75NTR can transduce the signal into the cell. Since the involvement of the shared residues 
seemed to be crucial for Aβ-induced cell death, we postulated that at least in this contest, 
p75NTR could signal cell death through a pathway similar to the one already characterized 
for TNFR1. 
In support of our idea many reports have showed that Aβ is able to trigger death in different 
cell types in which p75NTR is expressed: rat primary cortical neurons, NIH-3T3 and 
neuroblastoma cell stably expressing p75NTR. It is also known that Aβ activates different 
signaling pathways involving JNKs, p38/SAPK and the transcription factor NFkB (Kuner et 
al,1998;Yaar et al,2002;Costantini et al,2005; Yao et al,2005). Interestingly, all of these 
pathways are known to be activated in various cell context through the TNFR1-DD (PER 
JNK: De Smaele et al,2001: Tang et al,2001; Deng et al,2003; Li et al,2005; Kamata et al, 
2005). Furthermore, it has been recently reported that in MCF7 breast cancer cells the 
Tumor Necrosis Factor Receptor1-associated Death Domain protein (TRADD), the most 
proximal TNFR1 cytoplasmic adaptor protein, is able to interact with the p75NTR-DD (El 
Yazidi-Belkoura et al,2003). 
To address the question if TRADD can have a role in Aβ induced p75NTR-mediated 
cytotoxicity, we generated a dominant negative (DN) for TRADD. The HA-TRADD∆DD 
mutant lacks the Death Domain of the protein at the C-terminal end  and is HA-tagged at the 
N-terminal end.  
A TRADD deleted of the C-terminal domain cannot anymore interact with the TNFRI DD 
but can still interact with downstream factors through the N-terminal region. A similar 
mutant has been successfully used to block the activation of TNFR1- or p75NTR-dependent 
signaling pathways such as the Nf-κB, JNKs and p38/SAPK pathways through a dominant 
negative effect most likely elicited by titration of downstream factors, such as TNFR-
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associated factor-2 (TRAF2) (Kieser et al,1999; El Yazidi-Belkoura et al,2003). To validate 
the effectiveness of this reagent, we proceeded verifying if the TRADD∆DD mutant was 
actually able to interfere with a TNFR1-dependent cell death process. 
To do so we induced TNFRI overexpression in HEK293 cells, leading to the formation of 
trimeric receptor complex that mimic the activation induced by ligand. Thus, we performed 
experiments of co-transfection to study the role of the dominant negative, TRADD∆DD. To 
label the transfected cells we included a vector to express GFP in every transfection 
experiment. 
24 hours after transfection, cells have been fixed and stained with Hoechst 33342 and 
observed at the microscope to evaluate the number of transfected cell showing normal or 
apoptotic morphology. The transfected cells have been scored for the general cell 
morphology made evident by the ubiquitous expressed GFP, looking at the presence of the 
typical membrane blebbings and for the nuclear morphology, looking at the bright and 
condensed Hoechst staining. Indeed, overexpressed TNFR1 was able to trigger high level of 
cell death in HEK293 whereas co-transfection with the TRADD∆DD vector significantly 
reduced the number of dead cells. (fig. 2A) This experiment indicates that the TRADD∆DD 
is able to interfere with a TNFR1/TRADD dependent cell death process making it a suitable 
reagent to test if TRADD is also involved in Aβ induced p75NTR-mediated cytotoxicity in 
Neuroblastoma SK-N-BE cells. 
 
 
Fig. 3A Role of cytoplasmic adaptor TRADD in mediation of TNFRI depending cell death. The dominant negative 
effect of the TRADD truncated mutant (TRADD∆DD) has been validated in a known cell-death paradigm as TNFR1 
overexpression in transiently transfected HEK293 cells. HEK293 cells have been transiently co-transfected with a 
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plasmid to express EGFP to label transfected cells and an empty vector (pCEP) or plasmids to express TRNFRI alone 
(TNFR1), TRADD∆DD alone (TRADD∆DD) or TNFR1 and TRADD∆DD (TNFR1/TRADD∆DD). After 24 hrs cells 
have been fixed and stained with Hoechst 33342 and cell death has been assessed looking for nuclear condensation in 
GFP positive cells displaying round shape and membrane blebbing. Data are means + ES of three experiments. 
 
After validation of our dominant negative, we tested whether we could reproduce the same 
effect observed with TNFRI/TRADDDD also co-transfecting TRADD∆DD in cells 
expressing p75NTR. To this purpose SK-N-BE derived pools, selected after transfection of 
either p75NTR/pcDNA or pcDNA empty vectors, were further transfected with either 
TRADD∆DD/pCEP4 or pCEP4, the latter one used as negative control. After Hygromycin 
selection, pools of double transfected cells were collected, characterized both for p75NTR 
and for TRADD∆DD expression and cell pools expressing comparable level were analyzed 
for the cell death. No changes in the TRADD expression level have been detect with the 
overexpression of p75NTR. (Figure2B)  
 
Fig. 3B Expression level of SK-N-BE derived pools. Western-blotting analysis of total protein extracts obtained from 
SKNBE cell pools stably transfected with a pCDNA empty vector or a p75NTR/pCDNA vector to express wild type 
p75NTR. After SDS-PAGE of equal amount of total protein extract and transfer to nitrocellulose membrane, the blot has 
been probed with anti-p75NTR or anti-TRADD antibody as indicated. The panel shows that both cells expressing p75NTR 
and control cells express equal amount of endogenous TRADD protein. 
 
As described above, cells were exposed to either Aβ peptide or to the control peptide for 48 
hours and cell death has been evaluated after TUNEL labeling. As shown by the histogram 
in figure 3C, the treatment with Aβ in SK-N-BE expressing wild type p75NTR arose a 22% 
of dead cell. 
Expression of TRADD∆DD by itself does not affect in any way the level of cell death. The 
co-transfection p75NTR WT/TRADD∆DD shows a level of cytotoxicity comparable with 




Fig. 3C Role of the cytoplasmic adaptor TRADD in Aβ–induced p75NTR mediated cytotoxicity. A TRADD 
truncated mutant lacking the death domain (TRADD∆DD)generate a dominant negative effect in neuroblastoma cell 
line. A-SKNBE derived cell pools stably transfected with empty vectors (pcDNA), or plasmids to express p75NTR alone 
(p75NTR), TRADD∆DD alone (TRADD∆DD), p75NTR and TRADD∆DD (p75/TRADD∆DD), were selected and 
exposed to Aβ 25-35 (A-Beta) or to the control peptide A 35-25 (control). After 48 hrs cells were analyzed to assess 




Indeed, TRADD∆DD is able to interfere with the cytotoxic signal and almost to block Aβ-
induced p75NTR-mediated cell death. (fig 3C) These data suggest that, at least upon Aβ 
binding, p75NTR could signal cell death through a protein complex that involves a 

























1.3 p75NTR and TRADD interact mainly through the p75NTR/TNFR1 
conserved residues required for Aβ-induced cell death.. 
 
The reduced cell death levels observed in SK-N-BE pools expressing p75NTR-WT and 
TRADD∆DD, pushed us to verify whether TRADD could also be a direct interactor for 
p75NTR. The best way to address this question was to set up a Co-Immunoprecipitation 
Assay after transient transfection of HEK293 cells. Since it is known that TRADD is able to 
interact directly with TNFRI Death Domain but not with Fas-associating protein with death 
domain (FADD), the direct Fas cytoplasmic adaptor protein, we used these two death 
domain containing receptors respectively as positive and negative control. 
We generated expression vectors to express HA tagged versions of FADD (HA-FADD) and 












Fig. 4 Physical interaction between p75NTR and TRADD. Co-Immunoprecipitation Assays after transient transfection 
of HEK293 cells have been performed to compare the ability of p75NTR and TNFR1 to interact with the cytoplasmic 
adaptors: TRADD and FADD. (A) Schematic drawings of the transfected tagged-proteins: 3XFLAG-TNFR1, HA-
TRADD and HA-FADD. (B) After 24 hrs of transfection of indicated vectors, 1.5 mg of total protein extract has been 
used to immunoprecipitate HA-tagged TRADD or FADD. Western-blotting analysis has been done probing film with 
antibodies raised against the indicated epitopes: i) p75NTR antibody against p75NTR, flag antibody against FLAG-
TNFR1; HA antibody against HA-TRADD and HA-FADD. The shown autoradiographs are representative of at least 
three independent experiments. 
 
 
Indeed, the Co-Immunoprecipitation Assay showed that in the double transfection 
p75NTR/TRADD experiment, pulling down TRADD by HA antibody, we could co-
immunoprecipitate p75NTR, reproducing for p75NTR the same interaction that occurs 
between TNFR1 and TRADD. 
Notably, the importance and specificity of this results was highlighted by the absence of 
coimmunoprecipitation signal from the cotransfection of p75NTR and FADD expressing 
vectors. 
As already known and reproduced by our experiment in Fig. 4B, FADD does not interact 
with TNFRI even if it possesses a Death Domain. The fact that we did not find interaction 
between FADD and p75NTR gives more specificity and relevance to the observation of a 
phisical interaction between p75NTR and TRADD. In other words, the presence of a Death 
Domain is a required condition but not necessary to guarantee a protein-protein interaction 
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through Death Domain containig proteins and so the Co-Immunopracipitation 
TRADD/p75NTR likely reflects the existence of a real protein complex. 
Indeed, to investigate the possible role of a p75NTR/TRADD interaction in mediating the 
cytotoxic signal of Aβ, we tested if the p75NTR single substitution mutants could affect in 
some way the complex assembly. 
HEK293 cells have been co-transfected with plasmid to express HA-TRADD alone or 
together with either wild type p75NTR or the mutants p75E377A and p75W388A. As shown 
in Fig. 5, the p75E377A and p75W388A mutants have not been efficiently co-
immunoprecipitated by TRADD-HA as we observed for p75NTR WT. This could suggest 
that p75NTR mutants could fail to transduce the cytotoxic signal most likely because they 
cannot interact efficiently with TRADD. In agreement with our results, Telliez and 
collegues showed that the mutation E369A in TNFR1-DD (corresponding to p75NTR 
E377A) not only blocks TNFR1-dependent cell-death but also affects TNFR1-TRADD 
interaction (Telliez et al,2000). All together these data suggest that a p75NTR/TRADD 





Fig. 5. The p75NTR mutants that do not signal cytotoxicity have reduced ability to co-immunoprecipitate with 
TRADD. Transient transfection of HEK293 cells has been performed to compare the level of the Co-
Immunoprecipitation efficiency between wild type p75NTR (p75WT) and p75NTR mutants (p75E377A, p75W388A). 
After 24 hrs transfection of above indicated vectors, 1.5 mg of total protein extract has been used to immunoprecipitate 
HA-tagged TRADD followed by Western-blotting probed with antibodies raised against the indicated epitopes: i) 
p75NTR antibody against p75NTR ; HA antibody against HA-TRADD. The shown autoradiographs are representative of 
at least three independent experiments. 
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1.4 Aβ peptides modulates p75NTR-TRADD interaction. 
 
To assess the role of the p75NTR/TRADD interaction in a more physiologic setting, we 
investigated if the protein complex formation could be modulated by Aβ peptide exposure. 
We engineered SK-N-BE neuroblastoma cells to express both p75NTR and HA-tagged full 
length TRADD (HA-TRADD). Transfected cells have been selected to generate pools that 
we characterized for the p75NTR and HA-TRADD expression levels (data not shown). The 
selected cell pool has been exposed to Aβ peptides, or to control reverse peptides, for 1, 2, 
3, 4, 7, 8 hours. The time course has been done trying to reproduce the possible kinetic 
required to allow the binding of the Aβ to the receptor. After exposures, cells have been 
scraped and equal amount of crude cell protein extracts have been incubated on anti-HA 
agarose-beads. Following the Co-Immunoprecipitation protocol, complex have been eluted 
from the beads and separated on SDS-PAGE then transferred to a membrane that has been 
probed sequentially with anti-p75NTR and anti-HA antibodies to quantify the co-
immunoprecipitated p75NTR and the immunoprecipitated TRADD. As results from Fig 6, 
after 1 hour of treatment we could not detect p75NTR protein pulled down by HA-TRADD. 
Proceeding with a longer exposure of 2 and 4 hours, we noticed an increased amount of 
p75NTR co-immunoprecipitated with HA-TRADD. Prolonged treatments at 6-8 hours do 





Fig. 6. Aβ peptide modulates p75NTR/TRADD interaction. Time course of p75NTR/TRADD interaction: SKNBE cell 
pools stably transfected to express p75NTR and HA-TRADD or stably transfected with a pCEP4 empty vector have been 
exposed to Amyloid Beta peptide (Aβ) for 1, 2, 4, 6, 8 hrs. 1,5 mg total protein extract for each time course point has 
been used to immunoprecipitate HA-TRADD followed by Western-blotting probed with antibodies raised against the 
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indicated epitopes: i) p75NTR and HA-TRADD. The shown autoradiographs are representative of at least three 
independent experiments. 
 
Indeed, this result indicates that Aβ peptides can modulate and activate the interaction 
between p75NTR and TRADD. As showed, this activation occurs in a specific time-
dependent manner that peaks after 4 hours of exposure. 
Finally, we define a possible mechanism by which p75NTR can mediate cell death in an Aβ 
dependent manner, recruiting TRADD at the level of the membrane and transferring the 




















































In our study we discuss the role of the Neurotrophin Receptor p75NTR in mediating cell 
death induced by exposure to the Aβ peptide. The aim of our project is to investigate the 
molecular mechanisms that follow the binding of the peptide to the receptor peptide and 
mainly to identify the cytoplasmic pathway that are involved in the cell death signal. By 
deleting specific sequences in the intracellular domain of p75NTR, we already defined the 
essential role of the death domain (DD) as responsible for the signal transduction (Perini et 
al., 2002). Furthermore, in the present work we address in details why the DD is essential 
and in which way mediates cell death. We show for the first time that the membrane 
receptor p75NTR, upon binding to β-Amyloid (Aβ) peptide, is able to transduce a cytotoxic 
signal through a mechanism very similar to the one adopted by Tumor Necrosis Factor 
Receptor 1 (TNFR1), when activated by TNFα. 
Our first approach was based on the analysis of the tridimensional conformation of the 
receptor. This allowed us to identified specific residues in the DD that, when mutated to A, 
are no longer able to signal cell death. p75NTR belongs to the family of Tumor Necrosis 
Factors Receptor 1, this suggested us the possibility of a common mechanism to signal cell 
death. To test our hypothesis we considered the sequence homology between the death 
domains of p75NTR and TNFR1 and we identified few almost complete identical residues. 
By exposing to Aβ peptide neuroblastoma cell stably expressing p75NTR mutated versions  
we could indeed verify that those aminoacids (E377, W388, A397 and I411) are involved in 
mediating cell death. Since the residues shared between p75NTR and TNFRI seemed to be 
important for both the receptors for transducing the death signal (Tartaglia et al 1993) we 
further speculated about the putative cytoplasmic interactors involved in this process. The 
Neurotrophin receptor p75NTR is known to mediate different effects, from cell survival to 
cell death, into the cell most likely depending on which is the extracellular stimulus and on 
which are, among the many identified, the cytoplasmic interactors expressed in the 
considered cell type . A recent paper reported that in MCF7 cells, p75NTR binds the Tumor 
Necrosis Factor Receptor1-associated Death Domain protein (TRADD), one of the first 
player in the TNFRI depending pathway. (Kieser et al,1999; El Yazidi-Belkoura et al,2003). 
Considering all together these insights, we decided to test if TRADD could be involved in 
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mediating Aβ-induced p75NTR-dependent cell death. For this purpose we generated a 
TRADD dominant negative mutant lacking the death domain required for the interaction 
with the receptor. Coexpressing p75NTR and TRADD∆DD in Neuroblastoma cells we 
assessed that also in this contest, TRADD is involved in the mediating the cell death upon 
Aβ exposure. To confirm these preliminary indications we set up a Co-Immunoprecipitation 
assays in transiently transfected HEK293 cells that indeed proved the direct interaction 
between p75NTR and TRADD. The p75NTR and TRADD forming complex resembles the 
same initial step of TNFR1 dependent signal transduction pathway even though in a 
different contest. Furthermore, we verified that the Fas-associating protein with death 
domain (FADD), the direct Fas cytoplasmic adaptor protein, does not interact with 
p75NTR, although displaying a death domain. This can suggest the presence of a death 
domain could be a feature necessary but not sufficient to generate a protein-protein 
interaction. So we proved that TRADD is a good candidate to initiate the p75NTR-
dependent death signal transduction into the cytoplasm. 
Once assessed the involvement of TRADD  in the p75NTR dependent signaling pathway, 
we tried to clarify whether it could also be an important player in mediating Aβ induced cell 
death. As first approach, we challenged by Co-Ip the efficiency of the interaction between 
TRADD and two p75NTR mutants: p75E377A and p75W388A. In this case, we found that 
these two p75NTR mutants, that more than the others failed to signal Aβ cell death, have 
been co-immunoprecipitated with a lower efficiency compared to wild type p75NTR. This 
suggests that p75NTR mutants could be less efficient to transduce the cytotoxic signal most 
likely because they cannot interact efficiently with TRADD. These findings arise a possible 
involvement of TRADD as a mediator of the cell death signal induced by Aβ peptide. To 
deeper prove that TRADD contributes to the Aβ induced cell death of neuronal cells, we 
performed a time-course treatment on SK-N-BE pools expressing p75NTR to see if the Aβ 
peptide binding to p75NTR can modulate p75NTR physical interaction to TRADD. 
To this purpose, we monitored the efficiency of the interaction between p75NTR and 
TRADD at different time point after exposures to Aβ and we could assess that the complex 
formation is indeed modulated by the peptide since we could observe a time-dependent 
kinetic. 
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We observed that TRADD interacts with p75NTR raising a peak between 2 to 4 hrs after 
peptide exposure. This observation possibly correlates with the kinetic of the 
Aβ  sedimentation and the activation of the receptor. Indeed, the relatively slow kinetic of 
the p75NTR/TRADD interaction we observed can be explained by the low solubility level of 
aggregated Aβ peptide and is consistent with the activation of the downstream signaling 
pathways, JNK and p38/SAPK, previously described using our cell system (Costantini et 
al,2005). Collectively, our study proposes a new mechanism that underlies the neurotoxicity 
induced by Aβ peptide and mediated by the Neurotrophin receptor p75NTR. In this contest, 
multiple proteins have been so far claimed to be candidates for the Aβ depending cell death 
(Hashimoto Y et al., 2004), perhaps depending on the different neuronal cell populations 
considered. In this respect, it has been reported that neuronal cell death in AD is mediated in 
part by the interaction of Aβ with p75NTR. (Rabizadeh et al 1994). Aβ binding to p75NTR 
results in c- JUN N-terminal kinase (JNK) activation and apoptotic cell death in p75NTR 
expressing cells (Yaar et al 1997; Bhakar et al,2003; Becker et al, 2004; Ham et al,2005). 
Aβ activates nuclear factor- kB (Nf-κB) by binding to p75NTR in neuroblastoma cells 
(Kuner and Hertel, 1998). Furthermore, we proved that the p75NTR DD is responsible for 
the mediation of Aβ neurotoxicity (Perini et al, 2002). Finally, reflecting some similarity 
with the TNFR1, we map specific area in the DD of p75NTR responsible for the mediation 
of the Aβ cell death. This signal transduction recruits the new player, TRADD, to the 
membrane and activates the apoptotic pathway. In this study, we confirm the essential role 
of p75NTR in the mediation of the neurotoxicity depending on Aβ, even though we still 
have to verify the downstream pathway that ultimately activates the programmed cell death 
(Costantini et al, 2005). 
With our study we try to elucidate the role of p75NTR in the Aβ neurotoxicity, suggesting a 
possible molecular mechanism. In this respect, still a lot remains to be proved since the even 












Functional cooperation between TrkA and p75NTR 
accelerates neuronal differentiation by increased transcription 
of GAP-43 and p21(CIP/WAF) genes via ERK1/2 and AP-1 
activities 
 
2.1 p75NTR cooperates with TrkA to accelerate NGF-mediated neuronal 
differentiation 
To investigate how the expression of both p75NTR and TrkA can affect neuronal 
differentiation, we took advantage of SK-N-BE, a human neuroblastoma cell line which 
expresses neither receptors [67] although it can be committed to differentiate into 
sympathetic neurons upon treatment with retinoic acid or TPA [68,69]. SK-N-BE cells 
represent an interesting neuronal model in which it is possible to re-establish the expression 
of both receptors and study their reciprocal influence on the activation of specific signal 
transduction pathways. In the specific case, SK-N-BE cells were transfected with the 
appropriate vectors and stable cell pools (BEp75, BETrkA and BEp75/TrkA) were isolated 
and maintained in the appropriate selective medium (see Materials and methods for further 
details). As a control, cell pools carrying the empty vector (BE vector) were also generated. 
Expression of either TrkA or p75NTR was monitored by immunoblotting (Fig. 1) and 
receptor membrane localization was verified by fluorescent immunolabeling with specific 
antibodies (data not shown). Cell pools expressing comparable levels of the receptors were 
chosen for further analyses.  
 
 
Fig. 2.1 – Expression of TrkA and p75NTR in SK-N-BE derived cells. Total protein extracts 
from each cell pool (50 µg) were separated by SDS-PAGE, transferred onto a nylon membrane and 
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probed with either anti-Trk (C-14, Santa Cruz) or anti-p75NTR antibodies (9992). The position of 
protein molecular weight markers (kDa) is indicated. 
 
 
First, we studied whether NGF can induce neuronal differentiation in the selected cell pools. 
BEvector, BEp75, BETrkA and BEp75/TrkA cells were seeded at a density of 2.5×104/cm2 
and treated with NGF. Neurite outgrowth, taken as a marker of neuronal differentiation, was 
monitored at different time points (0, 24, 48, 72 h). As shown in Fig. 2A, 100 ng/ml NGF 
can only induce differentiation of cells expressing the TrkA receptor. A similar experiment 
was also conducted using 10 ng/ml NGF to show that NGF, even at very low 






Fig. 2 – NGF dependent differentiation of the cells.  Cells were seeded at a density of 2.5×104/cm2 in complete 
medium. (A) After 24 h cells were washed with 1× PBS and maintained in a 0.1% FBS medium containing 100 ng/ml 
of NGF. Pictures (200× magnification) of the differentiating cells were taken at an interval of 24 h. (B, C) 
Quantification of the rate of differentiation is expressed as the percentage of cells that display neurite outgrowth upon 
exposure to 100 ng/ml NGF (B) or 10 ng/ml NGF (C) Specifically neurite outgrowth was considered positive when the 
length of the neuritis was at least twice the cell body diameter. For each tested condition, 500 cells from 10 independent 
fields were counted and the standard error was calculated. 
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Quantification of the differentiation state, expressed as a percentage of cells displaying 
neurite outgrowth, is described in Fig. 2B (100 ng/ml NGF) and Fig. 2C (10 ng/ml NGF). 
Neurite outgrowth is significantly more pronounced in BEp75/TrkA than in BETrkA cells at 
24 and 48 h after NGF exposure (Figs. 2B, C), suggesting that coexpression of both 









































2.2 p75NTR enhances TrkA autophosphorylation 
 
To investigate the molecular basis of this phenomenon, we have initially studied whether 
p75NTR may affect the autophosphorylation state of TrkA. In fact, previous studies showed 
that p75NTR can modify TrkA function by increasing TrkA phosphorylation [26,27,70,71]. 
Therefore, we analyzed the degree of TrkA phosphorylation as a function of NGF treatment. 
Specifically, both BETrkA and BEp75/TrkA cells were treated with NGF for 10 min and 
then lysed to prepare cell extracts. TrkA was immunoprecipitated with anti-TrkA antibodies 
and analyzed by Western blotting with an antiphospho-tyrosine antibody. Results of Fig. 3 
show that TrkA phosphorylation is higher in cells expressing both receptors than in cells 
expressing TrkA alone. This observation, which is consistent with the idea that p75NTR can 
potentiate TrkA kinase activity, supports the view that a higher TrkA autophosphorylation 





Fig. 2.3  p75NTR stimulates TrkA autophosphorylation. BETrkA and BEp75/TrkA cell pools were analyzed for 
NGF-mediated autophosphorylation of TrkA. Cells, where indicated, were treated for 10 min with NGF (100 ng/ml) 
and then lysed. Total protein extracts were subjected to immunoprecipitation with specific anti-Trk antibodies. 
Immunoprecipitated complexes were separated by SDS-PAGE and transferred onto a nylon membrane. The filter was 
first probed with anti-phospho-tyrosine antibodies to establish the level of TrkA phosphorylation and then reprobed 
with anti-Trk antibodies to determine the total level of TrkA present in the immunoprecipitated samples. The molecular 





2.3 p75NTR contributes to TrkA signaling by prolonging ERK1/2 
activation 
 
Since it has been shown that ERK1/2 are involved in cell differentiation [37,40], we 
investigated how p75NTR may affect TrkA downstream signaling, with respect to the 
activation of the ERK1/2 pathway. Cells were serum-starved for 8 h and then treated with 
100 ng/ml NGF for 30 min. Afterward, cells were processed and protein extracts were 




Fig. 2.4 Effect of the combined expression of p75NTR and TrkA on ERKs activation. (A) Cells were serum starved 
for 8 h and then treated with NGF (100 ng/ml) for 30 min. Protein extracts were analyzed by Western blotting by using 
antibodies against phospho-ERK1/2. Total amount of loaded ERK1/2 was determined by re-probing the filter with anti-
 47 
ERK1/2. (B) ERK1/2 activation of BEp75/TrkA cells completely depends on the TrkA kinase activity. In addition to 
NGF (100 ng/ml), cells were pre-treated with K252a (0.2 µM), a specific TrkA kinase inhibitor. ERK1/2 activation was 
monitored as described above. (C) ERK1/2 activation is sustained in BEp75/TrkA cells. BETrkA and BEp75/TrkA cells 
were serum starved for 8 h and then treated with NGF (100 ng/ml). Phosphorylated and total ERK1/2 were revealed by 
Western blotting. JNK1/2 are not activated by NGF in BETrkA and BEp75/TrkA cells. JNK1/2 activation was detected 
by Western blotting using specific anti-phospho-JNK1/2 antibodies. Cell extracts prepared at different time points were 
analyzed. The filter was reprobed with anti-ERK1/2 or anti-JNK1 antibodies to determine the total amount of ERK1/2 
or JNK1 protein in each lane, respectively. (D) Quantification of phosphorylated ERK1/2 in both BETrkA and 
BEp75/TrkA was determined by densitometric analysis. Results are plotted as fold activation vs. the time points of NGF 
treatment. (E) ERK1/2 activation is sustained even in BEp75/TrkA cells exposed to 10 ng/ml NGF. The experiment has 
been performed as described for panel C. ERKs and Akt activity was monitored at different time points. Akt is activated 
at low level already at 15′ compared to 0′ both in BETrkA and BEp75/TrkA cells. (F) Quantification of phosphorylated 
ERK1/2 in both BETrkA and BEp75/TrkA cells was determined as described above. The diagram summarizes the 
results of three independent experiments. The standard error is indicated. 
 
As expected, NGF activates ERK1/2 only in TrkA expressing cells (Fig. 4A). Notably, the 
activation is significantly increased in cells carrying both receptors (Fig. 4A). The fact that 
NGF did not activate ERK1/2 in BEp75 cells may indicate that the enhancement of ERK1/2 
phosphorylation in BETrkA and BEp75/TrkA cells occurs through TrkA signalling 
exclusively. To address this point, we analyzed the effect of the K252a compound, a 
specific TrkA kinase inhibitor [72,73], on the activation of ERK1/2. Fig. 4B shows that the 
K252a completely blocks the phosphorylation of ERK1/2 in both BETrkA and BEp75/TrkA 
cells. Overall, these results indicate that in BEp75/TrkA cells, p75NTR cooperates with 
TrkA to stimulate ERK1/2 activation. To better understand the dynamics of how this occurs, 
we performed a time course experiment in which the level of ERK1/2 phosphorylation was 
monitored byWestern blotting at different time points after NGF treatment. The experiment 
was performed at two different concentrations of NGF (100 ng/ ml and 10 ng/ml, Figs. 4C 
and E, respectively). Quantification of results shows that phosphorylation of ERK1/2 peaks 
between 15 and 30 min in TrkA expressing cells and then quickly decays at basal levels 
(Figs. 4D, F). On the contrary, the level of phosphorylation of ERK1/2 in BEp75/TrkA cells 
is higher than that of BETrkA and is sustained for more than 1 h after NGF treatment. We 
have also analyzed the NGF-mediated activation of JNK1/2 in both BETrkA and 
BEp75/TrkA cells. Results of Fig. 4C indicate that JNK1/2 are not activated by NGF. 
Finally we have tested the effect of NGF (10 ng/ml) on Akt to verify whether Akt might 
also be involved in the differentiation process. Results of Fig. 4E show that Akt becomes 
weakly phosphorylated upon NGF treatment although we could not observe any difference 
in terms of intensity and kinetic of phosphorylation between BETrkA and BEp75/TrkA 
cells. Therefore, this result excludes that the AKT pathway may be primarily involved in the 
accelerated neuronal differentiation of BEp75/TrkA cells. Overall our findings suggest that, 
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at least, one of the downstream effects caused by the cooperation of p75NTR with TrkA is 
that of specifically enhancing and prolonging ERK1/2 activation. 
 
2.4 Sustained ERKs activation correlates with an increased AP-1 
transcriptional activity 
 
To understand how sustained ERKs activation may affect differentiation, we studied the 
activity profile of three transcription factors: CREB, NF-kB and AP-1, which under diverse 
circumstances were shown to be regulated by TrkA [45,49,74]. To this purpose, the in vivo 
activity of CREB, NF-KB and AP-1 was determined by using luciferase reporters designed 
to monitor the specific transcriptional function of each factor. Definite amounts of reporter 
vectors were transfected into BETrkA and BEp75/TrkA cells either stimulated or not with 





Fig. 5 Analysis of NGF-mediated transcription regulation in BETrkA and BEp75/TrkA cells. Transcriptional 
activity of CREB, NF-kB and AP-1 factors was monitored through a luciferase assay. BETrkA and BEp75/TrkA cells 
were independently transfected with 500 ng of CREB-Luc, NF-kB-Luc and AP-1-Luc reporter plasmids and 24 h later 
were treated with either BSA (0.1%) or NGF (100 ng/ml). Cell protein extracts were generated to measure the 
enzymatic activity of the luciferase. Fold induction of the transcriptional activity of the reporter is expressed as the ratio 
between the luciferase activity of treated and untreated cells. The diagram relative to CREB, NF-kB and AP-1 
summarizes the results of four independent experiments. Standard error is indicated. 
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Fig. 5 shows that NGF could induce transcription of NF-kB-Luc, CREB-Luc and AP-1-Luc 
reporters in both cell pools. However, NGF-mediated transcription of the AP-1-Luc reporter 
resulted significantly stronger in cells expressing both receptors than in cells expressing 
TrkA alone, whereas no relevant difference was observed with regard to NF-kB-Luc and 
CREB-Luc reporters [75]. Interestingly, NGF-mediated transcription of all reporter vectors 
was completely abolished by the K252a inhibitor, supporting the view that TrkA kinase 







































2.5 Activation of ERKs is required for NGF-mediated neuronal 
differentiation 
 
To confirm that the activation of ERKs is necessary to increase the AP-1 transcriptional 
activity of both BETrkA and BEp75/TrkA cells, U0126, a specific MEK1/2 inhibitor, which 
blocks ERKs activationwas used [76]. Three different concentrations of U0126 were 
employed tomonitor both neuronal differentiation and the luciferase activity of the AP-1-
Luc vector when transfected into the BETrkA or BEp75/TrkA cells.  
 
 
Fig. 2.6 NGF-mediated differentiation and AP-1 transcriptional activity require the activation of ERK1/2 in 
BETrkA and BEp75/TrkA cells. (A, B, D, E) Degree of differentiation of BETrkA and BEp75/TrkA cells was 
determined as a function of NGF (10 ng/ml) following pretreatments with either U0126 (0.5 µM, 1 µM, 5 µM) or 
PD098059 (1 µM, 5 µM, 10 µM) at 24 h (A, D) and 48 h (B, E) with U0126 and PD098059 being two specific MEK1/2 
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inhibitors. Quantitation of neurite outgrowth was assessed as described in Fig. 2B. (C, F) AP-1 driven luciferase activity 
was tested in BETrkA and BEp75/TrkA cells in response to NGF (10 ng/ml) and either U0126 (0.5 µM, 1 µM, 5 µM) 
(C), or PD098059 (1 µM, 5 µM, 10 µM) (F). Fold activation of the AP-1 reporter transcription was measured as 
described in Fig. 5. 
 
Results show that U0126 could blocks neuronal differentiation more effectively in 
BEp75/TrKA than in BETrkA cells (Figs. 6A, B). Moreover, AP-1-Luc activity was 
drastically reduced in BEp75/TrkA as a function of increasing concentrations of U0126 
(Fig. 6C). To confirm U0126 results, we have also tested the effect of PD098059, another 
MEK1/2 inhibitor [77,78]. We designed an experiment similar to that described for U0126 
in which we monitored neuronal differentiation and AP-1-Luc activity as a function of 
increasing doses of PD098059. Results show that PD098059 has a stronger inhibitory effect 
on BEp75/TrkA than on BETrkA cells (Figs. 6D–F). Overall, these results indicate that 
accelerated NGF induced differentiation and potentiation of the AP-1 factor transcriptional 
activity in BEp75/TrKA cells require ERK1/2 activation. To demonstrate that AP-1 activity 
is required for accelerated BEp75/TrkA cells differentiation, these cells were pretreated with 
NDGA (Nordihydroguaiaretic Acid) a specific AP-1 inhibitor [79,80]. Again, as for the 
other inhibitors employed in this study, NDGA could inhibits neuronal differentiation more 
effectively in BEp75/TrkA than in BETrkA cells (Figs. 7A, B) and could also drastically 




Fig. 2.7 – NGF-mediated differentiation requires AP-1 transcriptional activity. (A, B) Degree of differentiation of 
BETrkA and BEp75/TrkA cells was determined as a function of either NGF (10 ng/ml) or NGF plus NDGA (1 µM, 5 
µM), a specific AP-1 activity inhibitor, at 24 h (A) and 48 h (B). Quantification of neurite outgrowth was determined as 
described in Fig. 2B. (C) As a control of the NDGA effect, AP-1 driven luciferase activity was tested in BETrkA and 
BEp75/TrkA cells in response to NGF (10 ng/ml) and/or NDGA (1 µM, 5 µM). Fold activation of the AP-1 reporter 
transcription was measured as described in Fig. 5. 
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Taken together these results support the model in which a specific AP-1 activity is promoted 
in BEp75/TrkA cells upon NGF treatment and that such an activity is required for 
accelerated neuronal differentiation. 
Previous studies have shown that activation of the AP-1 factor by MAPK correlates with the 
increased transcription of GAP-43 and p21(CIP/WAF), two genes that participate to 
neuronal differentiation and cell growth arrest, respectively [59–63]. To understand whether 
the cooperative action of both NGF receptors may affect the expression of GAP-43 and p21 
(CIP/WAF) genes, we monitored the mRNA expression of the two genes in both BETrkA 
and BEp75/TrkA cells as a function of NGF treatment. Cells treated with NGF for 0, 24, 48 
and 72 h were processed in order to purify total RNA. The relative amount of both 
transcripts was determined by quantitative RT-PCR and normalized to that of the 





Fig. 2.8 – NGF stimulation of GAP-43 and p21(CIP/WAF) gene transcription requires AP-1 activity. (A, B) SK-
N-BE derived cells were treated with NGF (100 ng/ml) for 0, 24, 48 and 72 h. Relative mRNA expression of GAP-43 
(A) and p21(CIP/WAF) (B) genes was determined by quantitative real-time PCR. GAP-43 and p21(CIP/WAF) mRNAs 
levels were normalized to that of the GUSB housekeeping gene and expressed as fold induction with respect to them 
RNA level detected before NGF treatment, which has been set to 1. (C, D) Relative mRNA expression of GAP-43 (C) 
and p21(CIP/WAF) (D) genes was determined as a function of either NGF (10 ng/ml) or NGF plus NDGA (1 µM, 5 
µM) at 24 h. The results are an average of three independent experiments. Standard errors are indicated. 
 
Results of Figs. 8A and B show that mRNA expression of both genes is significantly higher 
in BEp75/TrkA cells than in cells expressing either one of the receptors. To further confirm 
a direct role of AP-1 in neuronal differentiation we quantified GAP-43 and 
p21(CIP/WAF)mRNA expression in BETrkA and BEp75/TrkA cells when, in addition to 
NGF, these cells were pretreated with NDGA. The results of this experiment (Figs. 8C, D) 
show that transcription reduction of both genes is significantly more pronounced in 
BEp75/TrkA than in BETrkA cells. Overall, our data support a model in which the 
cooperative action of both receptor eventually results in increased expression of GAP-43 







































In this study, we have focused our interest on how p75NTR may affect TrkA downstream 
signalling with respect to neuronal differentiation. Here, we have shown that p75NTR can 
cooperate with TrkA by modulating the activation of ERK1/2 in response to NGF and thus 
leading to an accelerated neurite outgrowth. We have analyzed this process at different 
levels. First, we have determined the degree of autophosphorylation of TrkA in the presence 
or absence of p75NTR and found that p75NTR increases the overall levels of TrkA 
phosphorylation. Second, we have monitored the activation of ERK1/2 as a function of the 
specific contribution of each Neurotrophin receptors and found that the combined 
expression of the receptors leads to a persistent ERK1/2 activation. Prolonged activation of 
ERK1/2 in BEp75/TrkA is dependent on TrkA autophosphorylation in that it is completely 
abated by the K252a a specific inhibitor of the TrkA kinase. This result indicates that the 
functional cooperation between p75NTR and TrkA is not achieved through the activation of 
parallel signal pathways that may eventually merge within the cell, but it is rather the result 
of a specific enhancement of TrkA signaling. Moreover, these findings suggest that the 
enhancement of TrkA phosphorylation may be causally related to the sustained activity of 
ERKs in BEp75/TrkA cells. Although it is clear that the exact mechanism remains to be 
elucidated, our results reveal that the NGF dependent ERK activity can be finely modulated 
by controlling the relative expression of TrkA and p75NTR. The persistent activation of 
ERK1/2 has been correlated to neuronal differentiation [37,40]. Moreover, recent reports 
have shown that NGF-mediated ubiquitination of TrkA can be enhanced by p75NTR 
causing prolonged and increased ERKs activation [81,82]. Our results are consistent with 
this view and show that sustained ERKs activity may play a specific role in accelerating the 
differentiation process. In addition, our findings point to a critical function of the AP-1 
transcription factor in this process. Comparative analysis of three distinct transcription 
factors CREB, NF-kB and AP-1, often studied as major effectors of p75NTR and TrkA 
signal pathways, reveals that the AP-1 transcriptional activity is significantly stronger in 
cells expressing both receptors than in those expressing just TrkA. Moreover, AP-1 activity 
and neurite outgrowth are completely abolished when cells are treated with U0126 or 
PD098059, two specific MEK1/2 inhibitors. Our results extend those described by Leppa 
and colleagues who found that the NGF-mediated differentiation of PC12 cells requires the 
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activation of ERK1/2 for induction of c-jun mRNA synthesis, as well as for phosphorylation 
of the AP-1 components [75]. Specifically, the fact that JNK1/2 as well as Akt is not 
involved in the functional activation of the AP-1 factor suggests that ERK1/2 may activate 
AP-1 post-translationally. In many reports, AP-1 has been related to the p75NTR apoptotic 
signalling whereas other factors such as CREB and NF-kB were considered to be more 
specifically involved in survival and/or differentiation [83,84]. It should be noted that also 
in our cell model, CREB and NF-κB transcriptional activities are stimulated 
in a NGF dependent manner, implying that they may participate to the differentiation 
process. However, our findings highlight a distinctive regulation of the AP-1 transcriptional 
activity specifically in determining the rate of neuronal differentiation. Such a regulation 
may be achieved by controlling the specific duration of ERKs activity through 
combinatorial expression of the two neurotrophin receptors. These findings highlight a 
molecular mechanism through which cells interpret differences in ERKs signal duration and 
give rise to distinctive biological outcomes [85]. In case of sustained ERKs 
phosphorylation, the activity of the AP-1 transcription factor is enhanced with consequential 
increased expression of the p21(CIP/WAF) and GAP-43 genes, the activity of which is 
respectively critical for cell growth arrest and differentiation [59–63]. This result is 
corroborated by experiments in which we have employed NDGA, a specific AP-1 inhibitor. 
To our knowledge this is the first study in which NGF signalling has been recapitulated 
step-by-step within a definite cell system from the role of the membrane receptors to the 
expression of critical genes linked to neurite outgrowth. These findings may help 
understand some aspects of neuronal development in which the controlled expression of 
both TrkA and p75NTR may determine the fate of neurons by accelerating target 

















































DNA Constructs  
The p75NTR constructs carrying point mutations were generated by Inverse Long-PCR 
protocol following manufacturer instructions (Herculase Enhanced DNA Polymerase, 
Stratagene) and using as template a pcDNA3 plasmid (Invitrogen) in which the rat p75NTR 
wild-type cDNA has been cloned (p75NTR/pcDNA). The primer sequences used for each 








Underlined codons in either forward or reverse primer sequence indicate the A codon used 
to create the mutation. Introduction of the desired single point mutations was verified by 
plasmid clone sequencing. 
The human TRADD and FADD full lenght cDNAs have been amplified by PCR from, 
respectively, SK-N-BE and HL-60 cells total RNA after retrotranscription. The following 
primers have been used: 
HTRADD5BAMF: 5’-CGGGATCCGCAGCTGGGCAAAATGGGCAC-3’  
HTRADD3ECOR: 5’-CGGAATTCCTAGGCCAGGCCGCCATTGG-3’ 
HFADDBAM1F: 5’-CGGGATCCGACCCGTTCCTGGTGC-3’ 
HFADDECO1R: 5’-CGGAATTCTCAGGACGCTTCGGAGG-3’.  
The BamHI and EcoRI sites included in the primers and located, respectively, at the 5’ and 
3’ ends of the RT-PCR products, were used to clone the cDNAs in the pRK7-HA expression 
vector to obtain in frame fusions with the HA epitope at the TRADD or FADD N-terminal. 
Afterward, the whole HA-TRADD cDNA has been amplified with the following forward 
primer:  
HA5HIND1F: 5’-CCCAAGCTTACCATGGCCTACCCCTACGACG-3’ and the following 
reverse primers:  
HTRADD3NHEIR:5’-CTAGCTAGCCTAGGCCAGGCCGCCATTGG-3’, 
HTRADDNEG3NHEIR: 5’-CTAGCTAGCCTACGGCGGCGGCGGCTTCAC-3’, 
to clone, respectively, the full-length or the C-terminal truncated HATRADD 
(HATRADD∆DD) in the HindIII/NheI sites of the pCEP4 expression vector multicloning 
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site (Invitrogen). The HATRADD sequence has been verified both in the pCEP/HATRADD-
FL and in the pCEP/HATRADD∆DD plasmids. 
The human TNFR1 full lenght cDNA has been amplified by RT-PCR from HL-60 cells total 
RNA using the following primers: 
TNFR1BAM1F: 5’-CGGGATCCGGCCTCTCCACCGTG-3’ 
TNFR1BAM1R: 5’-CGGGATCCTCATCTGAGAAGACTGGG-3’. 
The amplification product has been cut at the 5’ and 3’ ends by BamHI and ligated into the 
3xFLAG-CMV-10 expression vector (Sigma-Aldrich) after BamHI restriction reaction; the 
orientation of the TNFR1 cDNA respect to the plasmid vector has been assessed using a 
TNFR1 cDNA EcoRI asimmetric internal site. 
 
Cell Cultures and Transfection 
 
All cell lines were cultured at 37°C in 5% CO2. HEK 293 cells were grown in Dulbecco’s 
modified Eagle’s medium (DMEM), 2 mM L-glutamine, 10% fetal bovine serum (FBS) and 
50  mg/ml gentamycin. The human neuroblastoma SK-N-BE cell line was grown in DMEM 
containing 5% FBS, 10% HS (Horse serum), 2 mM L-glutamine, 50  mg/ ml gentamycin, 
250 ng/ml amphotericin B. Cells were transfected by using the polyethylene-immine method 
(PEI, Sigma). 
SK-N-BE derived cell pools stably transfected with the expression vectors pcDNA3Neo 
(Invitrogen) carrying the rat wild type (Rp75NTR) or the indicated mutant p75NTR cDNAs 
were selected in complete medium containing G418 (800mg/ml). SK-N-BE cell pools stably 
transfected with the Rp75NTR/pcDNA or the pcDNA empty vector were transfected with the 
pCEP4Hygro (Invitrogen) expression vector carrying either the wild type or the C-term 
truncated human HA tagged TRADD (HA-TRADD) cDNA or the pCEP4Hygro empty 
vector and were selected in complete medium containing Hygromycin (800  mg/ ml), and 
G418 (150mg/ml). Pools of stably transfected cell clones selected with the appropriate 
growth inhibitor, as indicated, were characterized by checking the transfected protein/s 
expression level by Western-blotting and p75NTR cell membrane localization was checked by 
immunofluorescence following the procedure described in Perini et al,2002. Cell pools 
displaying a comparable protein expression level have been selected for further experiments. 
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Immunoprecipitation and Western Blot Analysis 
 
To test the expression level of wild-type or mutant Rp75NTR and HA-TRADD in the stably 
transfected cell pools, cell were lysed in a buffer (Lysis buffer) containing: 150 mM NaCl, 
50 mM Tris pH 7,5, 0,1% NP40, 1 mM PMSF, 1mM NaPirofosfato, 1 mM 
NaOrtovanadato, 1x protease inhibitors cocktail, (Complete-Roche); this lysis procedure let 
to obtain a cell lysate enriched in membrane and cytoplasmic protein.  
Protein extracts were fractioned by 4-12% SDS-PAGE (NuPage system-Invitrogen) and 
elettroblotted to nitrocellulose filters (Amersham Bioscinces) that were blocked for at least 
30 min at room temperature in 5% nonfat dry milk in Tris-Cl pH 8.50 mM, NaCl 150 mM 
(blocking buffer) and incubated in blocking buffer overnight at 4°C with one of the 
following antibodies: anti-p75NTR 9992 polyclonal antiserum raised against the rat p75NTR 
intracellular region (Promega); anti-TRADD goat polyclonal antibody raised against C-
terminal aminoacidic sequence (Santa Cruz); anti-HA monoclonal antibody (Santa Cruz) to 
test the HATRADD-DN expression level. Membranes were washed three times in blocking 
buffer with 0,1% Tween-20 and incubated in the suitable secondary HRP-conjugated 
antibody (Jackson-Immunoresearch Lab.) for 1 h at room temperature. Membranes were 
then washed as before and signals revealed using ECL (Amersham Bioscences). 
The interaction between TRADD and p75NTR was assessed in SKNBE transfected cell pool 
at 2 to 8 h after Aβ peptide stimulation or in transiently transfected HEK 293 cells, as 
described in the text, by Immunoprecipitation and Western blotting. 
Cells were washed two times in PBS and lysed in lyses buffer. Cell lysate (1.5 mg) was 
precleared with protein A-agarose beads (Roche), (30 min at 4°C) and then 
immunoprecipitated with anti-HA Affinity Matrix overnight at 4°C. The day after, the beads 
with immunocomplexes were washed three times with lyses buffer and boiled in Laemmli 
sample buffer for 5 min at 100°. Eluted proteins were separated by SDS-PAGE and 
analyzed by Western blot with the indicated antibodies. 
 
Cell death assay 
 
SK-N-BE derived cell pools have been plated on 24-multiwell plate (3,5X104 cells/well); 
after 12-18 hours cells have been wash once with medium and exposed to the Aβ 25-35 
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peptide (Bachem) or to the control Aβ 35-25 peptide (Bachem) both diluted 20 µM in the 
culture medium. Peptide have been solved and prepared as described in Perini et al, 2002. 
After 48 hours cells were washed twice with PBS 1X, detached by gently pipetting and 
loaded in slide-carrying cell chamber to spin cells on the slide using Cytospin IV (Thermo 
Shandon) 4 min at 1000 rpm. Immediately after, cells have been fixed with cold 
Paraformaldehyde 4% in PBS 1X. After two wash with PBS 1X cells have been 
permeabilaized and labeled with the TUNEL technique following manufacturer instructions 
(TUNEL Cell Death Detection KIT-Roche). After the labeling reaction cell nuclei have 
been stained with Ethidium Bromide 0,7 µg/ml in PBS 1X for 7 min and then washed three 
time in PBS1X and mounted in antifading medium (Vectashield–Vector). The number of 
dead cells has been evaluated at the conventional fluorescent microscope (Zeiss-Axiophot) 
using selective band pass filter to detect the FITC-dTTP incorporation and filter to detect 
the ethidium bromide stain to check for nuclear localization of the TUNEL labeling. When 
indicated in the text cytotoxicity level has been evaluated also with a double Acridine 
orange/Ethidium Bromide in vivo staining as described (Perini et al,2002) To validate the 
antiapoptotic activity of TRADD∆DD truncated mutant, HEK 293 cells seeded on 
coverslips in a 6-well multiwells plate were transfected with plasmid vectors to express 
EGFP (to label transfected cells) and p75NTR or TRADD∆DD alone or together. After 12-18 
hrs from the transfection cells have been twice washed, fixed in cold paraformaldehyde 4% 


















The TrkA construct was produced by cloning the corresponding cDNA into pCEP9β vector 
(Invitrogen). The p75NTR constructs were generated as previously reported [64,65]. Cell 
culture and selection of transfected cells Neuroblastoma SK-N-BE [64] cells were grown in 
DMEM medium containing 10% horse serum, 5% FBS and 2.5 µg/ml of gentamycin. Cells 
were transfected with pCEP9β empty vector or pCEP9β-TrkA or pCEP4β-p75NTR 
constructs by using the polyethylene-immine method (PEI, Sigma-Aldrich) [66]. After 
transfection, cells were split and grown in complete DMEM medium containing either 400 
µg/ml of G418 (Roche) for the selection of TrkA positive pools of clones (BETrkA) or 150 
µg/ml of Hygromycin (Roche) for the selection of p75NTR positive pools of clones 
(BEp75). Selected cell pools were collected, expanded and characterized for expression of 
TrkA and p75NTR proteins by Western blotting. BETrkA cells were subjected to a second 
round of transfection with the pCEP4β- p75NTR construct to generate BEp75/TrkA cell 
pools. After transfection cells were split and grown in complete DMEM medium containing 
both G418 (400 µg/ml) and Hygromycin (150 µg/ml). Cell pools were selected and 
characterized for the expression of the receptors as described above. When indicated cells 
were serum starved for 8 h and then treated for additional 24, 48 and 72 h with 0.1% BSA, 
10 ng/ml or 100 ng/ml human recombinant NGF (Sigma) resuspended in a 0.1% BSA/PBS 
solution. When indicated cells were pre-incubated 1 h with0.2 µM K252a (Calbiochem), 
U0126 (0.5 µM, 1 µM, 5 µM; Cell Signalling), PD098059 (1 µM, 5 µM, 10 µM; Alexis 
Biochemicals) or NDGA-Nordihydroguaiaretic Acid (1 µM, 5 µM; Sigma-Aldrich) before 
adding NGF to the culture medium. Immunoprecipitation After NGF treatment, cells were 
washed with 1× ice-cold phosphate-buffered saline (PBS), and lysed in an IP-lysis buffer 
[20 mM Tris–HCl pH 7.5, 150 mM NaCl, 1% TRITON X-100, 100 mM NaF, 1 mM 
Na3VO4, 10% glycerol, 1 mM EDTA, 1 mM EGTA, 2 mM phenyl-methylsulfonyl fluoride 
(PMSF, Sigma) and a 1× protease inhibitor cocktail (Complete, Roche)]. The lysate was 
incubated on ice for 10 min and clarified by centrifugation. Proteins of each sample were 
quantitated by the BCA protein assay (Pierce).Two  milligrams of proteins from each 
sample was incubated O/N at 4 °C with an anti-Trk polyclonal antibody (C-14, Santa Cruz). 
ProteinA agarose beads (20 µl of 50% bead slurry-Pierce) were added, and samples were 
incubated for 3 h at 4 °C. Beads were collected, washed 3 times with 1× IP-lysis buffer and 
resuspended in 2× SDS sample buffer. IP-complexes were analyzed by immunoblot. 
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Immunoblot Cells were lysed in RIPA buffer, supplemented with phosphatase and protease 
inhibitors (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 1mMEDTA, 1mM Na3VO4, 100 mM NaF, 1× complete protease inhibitor 
cocktail, 1mMPMSF). Fifty micrograms of proteins was boiled for 5min in standard 1× 
sample buffer, separated on a 10% SDS polyacrilamide gel and blotted onto Hybond ECL 
nitrocellulose membranes (Amersham Pharmacia Biotech). Membranes were blocked and 
incubated O/N at 4 °C with the appropriate antiserum. Specifically, 9992 rabbit polyclonal 
antiserum raised against the intracellular region of p75NTR was a generous gift from Dr. 
M.V. Chao; anti-Trk(C-14), anti-ERK1/2(K-23) and anti-JNK1(C-17) were purchased from 
Santa Cruz; antiphospho- Tyr-100, anti-phospho-MAPK(ERK1/2), anti-phospho- 
SAPK/JNK, anti-phospho-Akt and anti-Akt were purchased from Cell Signaling; anti-actin 
was purchased from Sigma-Aldrich. Afterward, membranes were washed and incubated at 
room temperature for 1 h in blocking solution containing an HRP-conjugated anti-rabbit 
secondary antibody (Amersham Pharmacia Biotech). Signal was detected by using the ECL 
Western blotting detection reagents (Amersham Pharmacia Biotech). Luciferase assay 
2.5×105 cells/well were plated and grown for 24 h before transfection in a 24 well plate. 
Cells were washed with 1× PBS then transfected with 500 ng of the appropriate responsive 
reporter (CREB-Luc provided by E. Ciani, NF-kB-Luc provided by K.B. Marcu, AP-1-Luc 
provided by M. Karin) by using the PEI method. Cells were serum starved for 8 h and then 
treated for additional 24 h with 0.1% BSA, 10 ng/ml or 100 ng/ml NGF (Sigma-Aldrich). 
When indicated, cells were pre-incubated with K252a, U0126, PD098059 or NDGA before 
adding NGF to the culture medium. Firefly luciferase activity was normalized to that of 
Renilla luciferase included as an internal control. Luciferase activity was measured by using 
the Luciferase Assay System (Promega) with a TD 20/20 luminometer (Turner Designs). 
Real-time PCR Total RNA was extracted with TriReagent (Sigma-Aldrich). Thirty 
micrograms of total RNA was treated with DNASe Turbo (Ambion) to remove possible 
genomic DNA contamination. Two micrograms of DNA-free RNA was retrotranscribed 
with 5U of Thermoscript (Invitrogen) in a 20 µl volume for 1 h at 37 °C. RT reaction was 
brought to 100 µl final volume with DEPC water. Two microliters of the diluted RT 
reaction was used for QT-PCR using the IQ syber green supermix (Bio-Rad). QT-PCR was 
performed on an IQ5 Real-time PCR machine (Bio-Rad). Primers for QT-PCR were the 
following: AGCGTGGAGCAAGACAGTGG (GUSBf), 
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ATACAGATAGGCAGGGCGTTCG (GUSBr), GCAGGACGAGGGTAAAGAAGAGG 
(GAP-43f), GAGAAGAGGGTAGGGAGAGACAGG (GAP-43r), 
































Allen RT, Cluck MW, Agrawal DK, 1998. Mechanisms controlling cellular 
suicide: role of Bcl-2 and caspases. : Cell Mol Life Sci.;54(5):427-45. 
Ashkenazi A, Dixit VM, 1998. Death receptors: signaling and modulation. 
Science. 28;281(5381):1305-8. 
Barbacid M, 1994. The Trk family of neurotrophin receptos. J Neurobiol. 
25:1386-1403. 
Barde YA, Edgar D, Thoenen H, 1982. Purification of a new neurotrophic  
factor from mammalian brain. EMBO J. 1:549-553. 
Barde YA, 1989. Trophic factors and neuronal survival. Neuron. Jun;2(6):1525-
34. 
Barker PA, Shooter EM. 1994. Disruption of NGF binding to the low affinity 
neurotrophin receptor p75LNTR reduces NGF binding to TrkA on PC12 
cells. Neuron. ;13(1):203-15. 
Barker PA, 1998.   P75NTR: a study  in  contrasts. Cell Death Differ. 5: 346-
356. 
Barres BA, Raff MC, 1994. Control of oligodendrocyte number in the  
     developing rat optic nerve. Neuron.  May;12(5):935-42. 
Barret GL, Bartlett PF, 1994. The p75 nerve growth factor mediates survival or 
death depending on the stage of sensory neuron development. Proc Nat 
Acad Sci USA. vol. 91:6501-6505. 
Bamjii SX, Majdan M, Pozniak CD, Belliveau DJ, Aloyz R, Kohn J, Causin 
CG, Miller FD. 1998. The p75 neurotrophin receptor mediates neuronal 
apoptosis and is essential for naturally occurring sympatheic neuron death. 
J Cell Biol. 140:911-923. 
Barret GL, Bartlett PF. 1994. The p75 nerve growth factor mediates survival or 
death depending on the stage of sensory neuron development. In: Proc Nat 
Acad Sci USA. vol. 91:6501-6505. 
 68 
Benedetti M, Levi A, Chao MV, 1993. Differential expression of nerve growth 
factor receptors leads to altered binding affinity and neurotrophin 
responsiveness. : Proc Natl Acad Sci U S A. 15;90(16):7859-63. 
Bhattacharyya A, Watson FL, Bradlee TA, Pomeroy SL, Stiles CD, Segal 
RA. 1997. Trk receptors function as rapid retrograde signal carriers in the 
adult nervous system. J Neurosci. 17:7007-16. 
Bibel M, Hoppe E, Barde YA, 1999. Biochemical and functional interactions 
between the neurotrophin receptors trk and p75NTR. EMBO J. 1:616-22. 
Bilderback TR, Gazula VR, Lisanti MP, Dobrowsky RT. 1999. Caveolin 
interacts with Trk A and p75(NTR) and regulates neurotrophin signaling 
pathways. J Biol Chem. 274:257-63. 
Birren SJ, Lo L, Anderson DJ. 1993. Sympathetic neuroblasts undergo a 
developmental switch in trophic dependence. Development 119: 597-610. 
Bunone G, Mariotti A, Compagni A, Morandi E, Della Valle G. 1997. 
Induction of apoptosis by p75 neurotrophin receptor in human 
neuroblastoma cells. Oncogene 14:1463-70. 
Burek M, Oppenheim R. 1999. Cellular interactions that regulate programmed 
cell death in the developing vertebrate nervous system. Cell Death and 
Disease of thee Nervous System, ed. V Koliatsos, R Ratan, 1:145-80, 
Totowa: Humana. 
Carter BD, Lewin GR. 1997. Neurotrophins live or let die: does p75NTR 
decide? Neuron 18: 187-190. 
Casaccia-Bonnefil P, Carter BD, Dobrowsky RT, Chao MW. 1996. Death of 
oligodendrocytes mediated by the interaction of nerve growth factor with 
its receptor p75. Nature 383:716-719. 
Casademunt E, Carter BD, Benzel I, Frade JM, Dechant G, Barde Y-A. 
1999. The zinc finger protein NRIF interacts with yhe neurorophin 
receptor p75NTR and participates in programmed cell death. EMBO J. 
18:6050-6061. 
Chao MV, Bothwell MA, Ross AH, Koprowski H, Lanahan AA, Buck CR, 
Sehgal A. 1986. Gene transfer and molecular cloning of the human NGF 
receptor. Science 232:518-21. 
 69 
Chao MV, Hempstead BL, 1995. p75 and Trk: a two-receptor system. : Trends 
Neurosci. ;18(7):321-6. 
Chapman BS, 1995. A region of the 75 kDa neurotrophin receptor homologous 
to the death domains of TNFR-I and Fas. : FEBS Lett. 30;374(2):216-20. 
Chittka A, Chao MV. 1999. identification of a zinc finger protein whose 
subcellular distribution is regulated by serum and nerve growth factor. Proc 
Natl Acad Sci USA. 96:10705-10710. 
Cunningham ME, Greene LA. 1998. A function-structure model for NGF-
activated TRK. EMBO J. 17:7282-93. 
Davey F and Davies A M, 1998. TrkB signalling inhibits p75-mediated 
apoptosis induced by nerve growth factor in embryonic proprioceptive 
neurons. Curr Biol. 8:915-918. 
Davies AM. 1994. The role of neurotrophins in the developing nervous system. J   
Neurobiol. 25:1334-48. 
Dechant G, Barde YA, 1997. Signalling through the neurotrophin receptor 
p75NTR. Curr Opin Neurobiol.; 7(3):413-8. 
Dechant G, Barde YA. 2002. The neurotrophin receptor p75(NTR): novel 
functions and implications for diseases of the nervous system. Nat 
Neurosci.;5(11):1131-6. 
Dobrowsky RT, Werner MH, Castellino AM, Chao MV, Hannun YA. 1994. 
Activation of the sphingomyelin cycle through the low-affinity 
neurotrophin receptor. Science 265:1596-1599. 
Dobrowsky RT, Jenkins GM, Hannun YA. 1995. Neurotrophins induce 
sphingomyelin hydrolysis. Modulation by co-expression of p75NTR with 
Trk receptor. J Biol Chem. 270:22135-22142. 
El Yazidi-Belkoura I, Adriaenssens E, Dolle L, Descamps S, Hondermarck 
H, 2003. Tumor necrosis factor receptor-associated death domain protein 
is involved in the neurotrophin receptor-mediated antiapoptotic activity of 
nerve growth factor in breast cancer cells. J Biol Chem. 9;278(19):16952-
6.  
Esposito D, Patel P, Stephens RM, Perez P, Chao MV, Kaplan DR, 
Hempstead BL, 2001. The cytoplasmic and transmembrane domains of 
 70 
the p75 and Trk A receptors regulate high affinity binding to nerve growth 
factor. : J Biol Chem. 31;276(35):32687-95. 
Fahnestock M. 1991. Stucture and biosynthesis of the nerve growth factor. Curr 
Top Microbiol Immunol. 165:1-26. 
Frade JM, Barde YA. 1998. Microglia-derived nerve growth factor causes cell 
death in the developing retina. Neuron 20:35-41. 
Friedman WJ, Greene LA. 1999. Neurotrophin signaling via Trks and p75. Exp 
Cell Res. 253:131-42. 
Friedman WJ. 2000. Neurotrophins induce death of hippocampal neurons via 
the p75 receptor. J Neurosci. 2000 20:6340-6. 
Gargano N, Levi A, Alema S. 1997. Modulation of nerve growth factor 
internalization by direct interaction between p75 and TrkA receptors. J 
Neurosci Res. 50:1-12. 
Gotz R, Koster R, Winkler C, Raulf F, Lottspeich F, Schartl M, Thoenen H. 
1994. Neurotrophin-6 is a new member of the nerve growth factor family. 
Nature 372:266-9. 
Hallböök F, Ibanez CF, Persson H. 1991. Evolutionary studies of the nerve 
growth factor family reveal a novel member abundantly expressed in 
Xenopus ovary. Neuron 6:845-58.  
Hallböök F. 1999. Evolution of the vertebrate neurotrophin and Trk receptor 
gene families. Curr Opin Neurobiol. 9:616-621. 
Hannun YA. 1994. The sfingomieline cycle and the second messenger function 
of ceramide. J Biol Chem. 269:3125-3128. 
Hannun YA. 1996. Functions of ceramide in coordinating cellular responses to 
stress. Science 274:1855-1859. 
Harrington AW, Kim JY, Yoon SO, 2002. Activation of Rac GTPase by p75 is 
necessary for c-jun N-terminal kinase-mediated apoptosis. J Neurosci. 
1;22(1):156-66. 
Hefti F, 1986. Nerve growth factor promotes survival of septal cholinergic 
neurons after fimbrial transection. J Neurosci. 6:2155-62. 
 71 
Hempstead BL, Patil N, Thiel B, Chao MV, 1990. Deletion of cytoplasmic 
sequences of the nerve growth factor receptor leads to loss of high affinity 
ligand binding. J Biol Chem. 15;265(17):9595-8 
Hempstead BL, Rabin SJ, Kaplan L, Reid S, Parada LF, Kaplan DR. 1992. 
Overexpression of the trk tyrosine kinase rapidly accelerates nerve growth 
factor-induced differentiation. Neuron 9:883-96. 
Hofer MM, Barde YA, 19883 Brain-derived neurotrophic factor prevents 
neuronal death in vivo. Nature. 21; 261-2. 
Hohmann HP, Remy R, Poschl B, van Loon AP, 1990. Tumor necrosis 
factors-alpha and -beta bind to the same two types of tumor necrosis factor 
receptors and maximally activate the transcription factor NF-kappa B at 
low receptor occupancy and within minutes after receptor binding. J Biol 
Chem. 5;265(25):15183-8. 
Huang CS, Zhou J, Feng AK, Lynch CC, Klumperman J, DeArmond SJ, 
Mobley WC. 1999. Nerve growth factor signaling in caveolae-like 
domains at the plasma membrane. J Biol Chem. 274:36707-14. 
Ibanez CF. 1998. Emerging themes in structural biology of neurotrophic factors. 
Trends Neurosci. 21:438-444. 
Ip NY, Ibanez CF, Nye SH, McClain J, Jones PF, Gies DR, Belluscio L, Le 
Beau MM, Espinosa R 3rd, Squinto SP, et al. 1992. Mammalian 
neurotrophin-4: structure, chromosomal localization, tissue distribution, and 
receptor specificity. Proc Natl Acad Sci U S A. 89:3060-4. 
Irie S, Hachiya T, Rabizadeh S, Maruyama W, Mukai J, Li Y, Reed JC, 
Bredesen DE, Sato TA, 1999. Functional interaction of Fas-associated 
phosphatase-1 (FAP-1) with p75(NTR) and their effect on NF-kappaB 
activation. FEBS Lett 29;460(2):191-8. 
Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, 
Hase A, Seto Y, Nagata S, 1991. The polypeptide encoded by the cDNA 
for human cell surface antigen Fas can mediate apoptosis. Cell. 
26;66(2):233-43 
 72 
Itoh N, Nagata S, 1993. A novel protein domain required for apoptosis. 
Mutational analysis of human Fas antigen. : J Biol Chem. 
25;268(15):10932-7. 
Ivins KJ, Thornton PL, Rohn TT, Cotman CW, 1999. Neuronal apoptosis 
induced by beta-amyloid is mediated by caspase-8. Neurobiol 
Dis.;6(5):440-9. 
Jing S, Tapley P, Barbacid M. 1992. Nerve growth factor mediates signal 
transduction through trk homodimer receptors. Neuron. ;9(6):1067-79. 
Jones KR, Reichardt LF. 1990. Molecular cloning of a human gene that is a 
member of the nerve growth factor family. Proc Natl Acad Sci U S A. 
87:8060-64. 
Kaisho Y, Yoshimura K, Nakahama K. 1990. Cloning and expression of a 
cDNA encoding a novel human neurotrophic factor. FEBS Lett. 266:187-
91. 
Kanduc D, Mittelman A, Serpico R, Sinigaglia E, Sinha AA, Natale C, 
Santacroce R, Di Corcia MG, Lucchese A, Dini L, Pani P, Santacroce 
S, Simone S, Bucci R, Farber E, 2002. Cell death: apoptosis versus 
necrosis (review). Int J Oncol.; 21(1):165-70. 
Kaplan DR, Hempstead BL, Martin-Zanca D, Chao MV, Parada LF. 1991a. 
The Trk proto-oncogene product: a signal trasducing receptor for the nerve 
growth factor. Science 252:554-558. 
Kaplan DR, Martin-Zanca D, Parada LF, 1991b. Tyrosine phpsphorylation 
and tyrosine kinasi activity of the trk proto-oncogene product induced by 
NGF. Nature. 350:155-160. 
Kerr JRF, Wjllie AH, Currie AR. 1972. Apoptosis: a basic biological 
phenomenon with wide- ranging implications in tissue kineics. Br. J. 
Cancer. 26:239-257. 
Klein R, Jing SQ, Nanduri V, O'Rourke E, Barbacid M. 1991. The trk proto-
oncogene encodes a receptor for nerve growth factor. Cell 65:189-97. 
Krammer PH, Sartorius U, Schmitz I, 2001. Molecular mechanisms of death-
receptor-mediated apoptosis. Chembiochem. Jan 8;2(1):20-9. 
 73 
Kuner P, Schubenel R, Hertel C, 1998. Beta-amyloid binds to p57NTR and 
activates NFkappaB in human neuroblastoma cells. J Neurosci Res. 
15;54(6):798-804. 
Khursigara G, Bertin J, Yano H, Moffett H, DiStefano PS, Chao MV, 2001. 
A prosurvival function for the p75 receptor death domain mediated via the 
caspase recruitment domain receptor-interacting protein 2. J Neurosci. 
15;21(16):5854-63. 
Lachance C, Belliveau DJ, Barker PA, 1997. Blocking nerve growth factor 
binding to the p75 neurotrophin receptor on sympathetic neurons 
transiently reduces trkA activation but does not affect neuronal survival. : 
Neuroscience. ;81(3):861-71. 
Lai KO, Fu WY, Ip FC, Ip NY. 1998. Cloning and expression of a novel 
neurotrophin, NT-7, from carp. Mol Cell Neurosci. 11:64-76. 
Lamballe F, Klein R, Barbacid M. 1991. trkC, a new member of the trk family 
of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell 66:967-79.  
Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengerer B, Masiakowski P, 
Thoenen H, Barde YA, 1989. Molecular cloning and expression of brain-
derived neurotrophic factor. Nature. 14:149-352.  
Lee K-F, Davies AM, Jaenisch R. 1994. p75-deficient embryonic dorsal  root 
sensory and neonatal sympathetic neurons display a decreased sensitivity 
to NGF. Development 120:1027-1033. 
Levi-Montalcini R. 1951 Selective growth-stimulating effects of mouse 
sarcomas on the sensory and sympathetic nervous system of chick 
embryos. J.Exp.Zool 116:321-62 
Levi-Montalcini R. 1987. The nerve growth factor: thirty-five years later. 
Science 237:1154-1164. 
Levi-Montalcini R, Hamburger V, 1951. Selective growth stimulating effects 
of mouse sarcoma on the sensory and sympathetic nervous system of the 
chick embryo. J Exp Zool. ;116(2):321-61. 
Levi-Montalcini R, Hamburger V, 1953. A diffusible agent of mouse sarcoma. 
J Exp Zool.;123:233-87. 
 74 
Lewis M, Tartaglia LA, Lee A, Bennett GL, Rice GC, Wong GH, Chen EY, 
Goeddel DV, 1991. Cloning and expression of cDNAs for two distinct 
murine tumor necrosis factor receptors demonstrate one receptor is species 
specific. Proc Natl Acad Sci U S A. 1;88(7):2830-4. 
Liepinsh E, Ilag LL, Otting G, Ibanez CF, 1997. NMR structure of the death 
domain of the p75 neurotrophin receptor. EMBO J.15;16(16):4999-5005.  
Lindsay RM, Wiegand SJ, Altar CA, Distefano PS. 1994. Neurotrophic 
factors–from molecule to man. Trends Neurosci. 17:182-190. 
Mahadeo D, Kaplan L, Chao MV, Hempstead BL. 1994. High affinity nerve 
growth factor binding displays a faster rate of association than p140trk 
binding. Implications for multi subunit polypeptide receptors. J. Biol. 
Chem. 269:6884-6891. 
Maisonpierre PC, Belluscio L, Squinto S, Ip NY, Furth ME, Lindsay RM, 
Yancopoulos GD, 1990. Neurotrophin-3: a neurotrophic factor related to 
NGF and BDNF. Science. Mar 247:1446-51.  
Majadan M, Miller FD. 1999. Neuronal life and death decision: functional 
antagonism between the Trk and p75 neurotrophin receptors. Int J Dev. 
Neurosci. 17:153-161. 
Martin-Zanca D, Hughes SH, Barbacid M. 1986. A human oncogene formed 
by the fusion of truncated tropo-myosin and protein tyrosine knase 
sequences. Nature 319: 743-748. 
Martin-Zanca D, Oskam R, Mitra G, Copeland T, Barbacid M. 1989. 
Molecular and biochemical characterization of the human trk proto-
oncogene. Mol Cell Biol. 9:24-33. 
McDonald NQ, Lapatto R, Murray-Rust J, Gunning J, Wlodawer A, 
Bundell TL. 1991. A new protein fold revealed by a 2.3 Å resolution 
crystal structure of nerve growth factor. Nature 354:411-414. 
McKay SE, Garner A, Caldero J, Tucker RP, Large T, Oppenheim RW, 
1996. The expression of trkB and p75 and the role of BDNF in the 
developing neuromuscular system of the chick embryo. Development. 
Feb;122:715-24. 
 75 
 Middlemas DS, Lindberg RA, Hunter T. 1991. trkB, a neural receptor protein-
tyrosine kinase: evidence for a full-length and two truncated receptors. 
Mol Cell Biol. 11:143-53.  
Mukai J, Hachiya T, Shoji-Hoshino S, Kimura MT, Nadano D, Suvanto P, 
Hanaoka T, Li Y, Irie S, Greene LA, Sato TA, 2000. NADE, a p75NTR-
associated cell death executor, is involved in signal transduction mediated 




Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, 
Richards S, Dhein J, Trauth BC, 1992. Purification and molecular 
cloning of the APO-1 cell surface antigen, a member of the tumor necrosis 
factor/nerve growth factor receptor superfamily. Sequence identity with the 
Fas antigen. : J Biol Chem. 25;267(15):10709-15. 
Okamoto T, Schlegel A, Scherer PE, Lisanti MP, 1998. Caveolins, a family of 
scaffolding proteins for organizing "preassembled signaling complexes" at 
the plasma membrane. J Biol Chem. 6;273(10):5419-22 
Perez P, Coll PM, Hempstead BL, Martin-Zanca D, Chao MV. 1995. NGF 
binding to the trk tyrosine kinase receptor requires the extracellular 
immunoglobulin-like domains. Mol Cell Neurosci. 6:97-105. 
Perini G, Della-Bianca V, Politi V, Della Valle G, Dal-Pra I, Rossi F, Armato 
U, 2002. Role of p75 neurotrophin receptor in the neurotoxicity by beta-
amyloid peptides and synergistic effect of inflammatory cytokines. : J Exp 
Med. 1;195(7):907-18.  
Rabizadeh S, Bitler CM, Butcher LL, Bredesen DE, 1994. Expression of the 
low-affinity nerve growth factor receptor enhances beta-amyloid peptide 
toxicity. : Proc Natl Acad Sci U S A. 25;91(22):10703-6. 
Rabizadeh S, Oh J, Zhong LT, Yang J, Bitler CM, Butcher LL, Bredesen 
DE. 1993. Induction of apoptosis by the low affinity NGF receptor. 
Science. 261:345-348.  
 76 
Rabizadeh S, Bredesen DE, 2003. Ten years on: mediation of cell death by the 
common neurotrophin receptor p75(NTR). : Cytokine Growth Factor 
Rev.;14(3-4):225-39.  
Radeke MJ, Misko TP, Hsu C, Herzenberg LA, Shooter EM. 1987. Gene 
transfer and molecular cloning of the rat nerve growth factor receptor. 
Nature 325:593-596.  
Rettig WJ, Thomson TM, Spengler BA, Biedler JL, Old LJ, 1986. 
Assignment of human nerve growth factor receptor gene to chromosome 
17 and regulation of receptor expression in somatic cell hybrids. Somat 
Cell Mol Genet.;12(5):441-7.  
Reynolds AJ, Heydon K, Bartlett SE, Hendry IA. 1999. Evidence for 
phosphatidylinositol 4-kinase and actin involvement in the regulation of 
125I-beta-nerve growth factor retrograde axonal transport. J Neurochem. 
73:87-95. 
Riccio A, Pierchala BA, Ciarallo CL, Ginty DD. 1997. An NGF-TrkA-
mediated retrograde signal to transcription factor CREB in sympathetic 
neurons. Science 277:1097-100. 
Rodriguez-Tebar A, Dechant G, Barde YA., 1990. Binding of brain-derived 
neurotrophic factor to the nerve growth factor receptor. Neuron. 4(4):487-
92.  
Roux PP, Barker PA, 2002. Neurotrophin signaling through the p75 
neurotrophin receptor. Prog Neurobiol.; 67(3):203-33. 
Salehi AH, Roux PP, Kubu CJ, Zeindler C, Bhakar A, Tannis LL, Verdi 
JM, Barker PA. 2000. NRAGE, a novel MAGE protein, interacts with 
the p75 neurotrophin receptor and facilitates nerve growth factor-
dependent apoptosis. Neuron 27:279-88.  
Sartorius U, Schmitz I, Krammer PH, 2001. Molecular mechanisms of death-
receptor-mediated apoptosis. Chembiochem. 8;2(1):20-9. 
Senger DL, Campenot RB. 1997. Rapid retrograde tyrosine phosphorylation of 
trkA and other proteins in rat sympathetic neurons in compartmented 
cultures. J Cell Biol. 138:411-21. 
 77 
Soilu-Hanninen M, Ekert P, Bucci T, Syroid D, Bartlett PF, Kilpatrick TJ. 
1999. Nerve growth factor signaling through p75 induces apoptosis in 
Schwann cells via a Bcl-2-independent pathway. J Neurosci. 19:4828-38.  
Sofroniew MV, Galletly NP, Isacson O, Svendsen CN, 1990. Survival of adult 
basal forebrain cholinergic neurons after loss of target neurons. Science. 
247:338-42. 
Sofroniew MV, Howe CL, Mobley WC. 2001. Nerve Growth Factor Signalling, 
Neuroprotection, and Neural Repair. Annu. Rev. Neurosci. 24:1217-281. 
Squinto SP, Stitt TN, Aldrich TH, Davis S, Bianco SM, Radziejewski C, 
Glass DJ, Masiakowski P, Furth ME, Valenzuela DM, 1991. trkB 
encodes a functional receptor for brain-derived neurotrophic factor and 
neurotrophin-3 but not nerve growth factor. Cell. 31;65(5):885-93. 
Taniuchi M, Clark HB, Johnson Lr EM, 1986. Induction of nerve growth 
factor receptor in Schwann cells after axotomy. Proc Natl Acad Sci USA. 
83:4094-8. 
Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA Jr, Goeddel 
DV, 1991. The two different receptors for tumor necrosis factor mediate 
distinct cellular responses. : Proc Natl Acad Sci U S A. 15;88(20):9292-6. 
Tartaglia LA, Ayres TM, Wong GH, Goeddel DV, 1993. A novel domain 
within the 55 kd TNF receptor signals cell death. Cell. 10;74(5):845-53 
Telliez JB, Xu GY, Woronicz JD, Hsu S, Wu JL, Lin L, Sukits SF, Powers 
R, Lin LL, 2000. Mutational analysis and NMR studies of the death 
domain of the tumor necrosis factor receptor-1. : J Mol Biol. 
28;300(5):1323-33. 
Tsukamoto E, Hashimoto Y, Kanekura K, Niikura T, Aiso S, Nishimoto I, 
2003. Characterization of the toxic mechanism triggered by Alzheimer's 
amyloid-beta peptides via p75 neurotrophin receptor in neuronal hybrid 
cells. J Neurosci Res. 1;73(5):627-36. 
Tucker KL, Meyer M, Barde YA, 2001. Neurotrophins are required  for nerve 
growth during development. Nat Neurosci. 4:29-37. 
 78 
Ultsch MH, Wiesmann C, Simmons LC, Henrich J, Yang M, Reilly D, Bass 
SH, de Vos AM., 1999. Crystal structures of the neurotrophin-binding 
domain of TrkA, TrkB and TrkC. : J Mol Biol. 2;290(1):149-59. 
Urfer R, Tsoulfas P, O'Connell L, Shelton DL, Parada LF, Presta LG., 1995. 
An immunoglobulin-like domain determines the specificity of 
neurotrophin receptors. EMBO J. 15;14(12):2795-805. 
Urfer R, Tsoulfas P, O'Connell L, Hongo JA, Zhao W, Presta LG., 1998. 
High resolution mapping of the binding site of TrkA for nerve growth 
factor and TrkC for neurotrophin-3 on the second immunoglobulin-like 
domain of the Trk receptors. J Biol Chem. 6;273(10):5829-40.  
Vandenabeele P, Denecker G, Vercammen D, Declercq W,  2001. Apoptotic 
and necrotic cell death induced by death domain receptors. Cell Mol Life 
Sci.;58:356-70. 
Verdi JM, Birren SJ, Ibanez CF, Persson H, Kaplan DR, Benedetti M, Chao 
MV, Anderson DJ. 1994. p75(LNGFR) regulates trk signal transduction 
and NGF-induced neuronal differentiation in MAH cells. Neuron 12:733-
745. 
Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S, 
1992. Lymphoproliferation disorder in mice explained by defects in Fas 
antigen that mediates apoptosis. Nature. 26;356(6367):314-7. 
Windisch JM, Marksteiner R, Lang ME, Auer B, Schneider R., 1995.  
Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 
bind to a single leucine-rich motif of TrkB. Biochemistry. 5;34(35):11256-
63. 
Wolf DE, McKinnon CA, Daou MC, Stephens RM, Kaplan DR, Ross AH. 
1995. Interactions with TrkA immobilizes p75 in the high affinity nerve 
growth factor receptor complex. J Biol Chem. 270:2133-2138. 
Yaar M, Zhai S, Pilch PF, Doyle SM, Eisenhauer PB, Fine RE, Gilchrest 
BA, 1997. Binding of beta-amyloid to the p75 neurotrophin receptor 
induces apoptosis. A possible mechanism for Alzheimer's disease. : J Clin 
Invest. 1;100(9):2333-40.  
 79 
Yamashita T, Tucker KL, Barde YA. 1999. Neurotrophin binding to the p75 
receptor modulates Rho activity and axonal outgrowth. Neuron 24:585-93. 
Ye X, Mehlen P, Rabizadeh S, VanArsdale T, Zhang H, Shin H, Wang 
JJL,Leo E, Zapata J, Hauser CA Reed JC, Bredesen DE. 1999. TRAF 
family proteins interact with the common neurotrophin receptor and 
modulate apoptosis induction. J Biol Chem. 274:30202-30208. 
Yoon SO, Cassaccia-Boneffil P, Carter BD, Chao MV. 1998. Competitive 
signaling between TrkA and p75 nerve growth factor receptors determines 
cell survival. J Neurosci. 18: 3273-3281. 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
